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Abstract 
Signal transduction and stage-specific gene expression are essential 
components of Plasmodium falciparum development.  In this study, the putative 
phosphatase PF13_0027 is investigated as a critical component of 
intraerythrocytic development contributing to maturation of the late trophozoite.  
This putative phosphatase was identified during the course of a large-scale 
insertional mutagenesis project by insertion of the piggyBac (pB) element, 
containing a human dihydrofolate reductase (hDHFR) drug selection cassette 
into the open reading frame (ORF) preventing expression and attenuating 
parasite development.  PF13_0027 codes for a protein with a rhodanese (RHD) 
and dual specificity phosphatase (DUSP) in a tandem arrangement typically 
identified with mitogen-activated protein kinase (MAPK) phosphatases (MKP).  
Despite numerous INDELs, the tertiary structure is conserved when compared to 
the solved structures of MKP homologs.  The expression profile reveals 
transcripts at all stages of the blood cycle with a highest relative abundance in 
the late trophozoite.  Restoration of the phenotype was achieved through genetic 
complementation using the complete PF13_0027 open reading frame (ORF) 
under the control of its endogenous promoter.  A homology model of PF13_0027 
was developed for structural analysis and evaluated using in silico high-
 x 
 
throughput screening (HTS) to identify antimalarial compounds with predicted 
affinity to the active site and used to challenge parasites in vitro. This study 
reveals that PF13_0027 is a vital component of asexual development and a 
potential target for a new class of antimalarial compounds targeting 
phosphorylation pathways in P. falciparum.  Discovery of the functional role of 
this unknown ORF provides additional insight into the importance of MAPK 
signaling in P. falciparum. 
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Chapter 1:  Background and Introduction  
Malaria: A Global View 
Malaria is a devastating disease responsible for approximately 800,000 
deaths and 250 million clinical illnesses annually [10-12].  Clinical disease 
resulting from malaria is caused by cyclic intraerythrocytic development of the 
parasites in the blood [13-15].  This cycle of development is highly dependent on 
a progressive pattern of gene expression, and it is widely believed that the 
observed cyclical pattern of malaria parasites is ‘hard wired’ into the genome in 
contrast with most eukaryotic organisms that can variably regulate cell cycle 
development [16-20].  The protozoan parasites responsible for this disease have 
a history stretching back as far as 30 million years and have been mentioned 
throughout recorded history [21-25].  These parasites belong to the phylum 
apicomplexa and there are five species of Plasmodium known to infect humans; 
P. falciparum, P, vivax, P. malariae, P. ovale, and P. knowlesi [26, 27].  Of these 
five species, P. falciparum is the most severe and thought to have originated in 
Africa about 10 000 years ago [26-34].  To overcome the chronic and widespread 
nature of this disease there is an urgent need for vaccines to prevent infection 
and new drugs for prophylaxis and curative treatments [29, 35, 36].  Currently, 
many of the antimalarial drugs used to control malaria are rapidly losing their 
 2 
 
efficacy due to the adaptations of the parasite and the common chemical nature 
and targets of many current drugs [20, 37-40].  In the effort to develop new 
therapies, studies interpreting the genome have been vital to the understanding 
of Plasmodium biology [10].  The completed sequencing of the P. falciparum 
genome in 2002 has contributed a lot of vital information to this effort, but 
converting that information into new therapies has been slow due to the high 
quantity of encoded hypothetical genes and unknown ORFs [10]. 
Forward Genetics with piggyBac Transposon-mediated Mutagenesis 
Due to the lack of robust molecular genetic tools for manipulating the 
Plasmodium genome, translation of the genomic information to chemotherapeutic 
strategies has been an arduous process [41-43].  Of all the developmental 
stages in P. falciparum, the blood stages are the only stage that can be 
effectively cultured in vitro [44-46].  This stage is also the only one amenable to 
transfection with exogenous DNA [44, 47].  To investigate the Plasmodium 
genome, our lab uses random insertional mutagenesis with the transposable 
element piggyBac (pB) [9, 48].  Through this method, we have been able to 
identify genes important for the development of P. falciparum through individual 
gene knockouts followed by phenotypic characterization [9].  One of the main 
advantages to this method is that it has proven to be quicker and more efficient 
than homologous recombination, which is a lengthy process (6-12 months) 
requiring individual targeting plasmids for each recombination [9, 45, 46, 49-52].  
With the pB mutagenesis method, we have been able to knock out several genes 
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in the genome of P. falciparum, providing new avenues for in depth 
characterization of the genome (Figure 1.1).  Throughout this process, the 
putative phosphatase PF13_0027 was identified as important to intraerythrocytic 
development.  Further investigation revealed that the structure of PF13_0027 is 
conserved with MKPs and may provide insight into a more complex underlying 
signal transduction pathway.  This novel putative phosphatase could potentially 
develop much needed avenues for future antimalarial drug design. 
Global Impact of Malaria 
Malaria has been a huge problem in endemic regions throughout history; 
however, in the past century progress has been made successfully reducing the 
incidence of malaria in some endemic regions.  In recent times major advances 
controlling malaria have occurred in Sub-Saharan Africa, which experiences the 
greatest burden due to malaria.  The burden of malaria in this region is mainly 
fueled by the prevalence of the vector Anopheles gambiae, a long lived mosquito 
that feeds predominantly on humans and has been effective in transmitting 
malaria from person to person [53].  The most common cause of severe malaria, 
and the cause of most cases in Africa are the result of P. falciparum (Figure 1.2) 
infection, while P. vivax (Figure 1.3) is the most common cause of malaria 
outside of Africa [54-58]. 
Fortunately some progress has been made in controlling the effects of 
malaria in endemic regions.  Reported malaria cases in 2000 to 2010 decreased 
more the 50% in 43 of the 99 countries with ongoing transmission.  Downward 
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trends of 25-50% were observed in 8 other countries while global incidence of 
malaria was reduced by 17% since 2000 with mortality rates reduced by 26% 
[59].  According to the World Malaria Report released by the World Health 
Organization (WHO) in 2011, this target fell short of the international goal of 50%; 
however, it is still a major achievement.  Conversely, the global reach of malaria 
still threatens approximately 40% of the earth’s population in tropical and 
subtropical regions [33, 60, 61].  In Sub-Saharan Africa, this disease is both a 
cause and consequence of poverty, having an economic impact that slows 
growth by 1.3% annually, translating into a gross domestic product cost of $12 
billion [38, 62, 63].  Most cases of the most severe form of malaria, P falciparum, 
are confined to the continent of Africa accounting for approximately 90% of all 
deaths [53, 59].  Globally 86% of all malaria cases are children under the age of 
five [38, 64].   
To understand the larger picture of malaria’s effect within endemic regions 
it is necessary to have an effective method in place to track and record its 
impact.  Tracking and measuring malaria prevalence is an arduous process 
which is undertaken utilizing a variety of methods.  These approaches have both 
advantages and disadvantages, but they provide critical information supporting 
strategies aimed at controlling and eradicating malaria.  Four of the methods 
used for measuring malaria transmission are; entomological inoculation rate 
(EIR), parasite rate (PR), annual parasite index (API), and spleen rate (SR).  The 
EIR is a measure of infectious bites per unit time (usually one year), and is 
considered a direct reflection of the vector control and gametocytocidal drugs 
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[65, 66].  One of the drawbacks to this method is that there are not any standard 
protocols, so there is variability in the methodologies, and there are few 
specialists trained in the technique.  It was found that in some cases false 
positives from enzyme-linked immunosorbent assay (ELISA) techniques 
detecting circumsporozoite protein (CSP) could lead to an overestimation of EIR 
[67].  The PR looks at the proportion of the population carrying asexual stage 
parasites in the blood and can assess the gametocyte rates by age group.  An 
advantage of this method is that it provides a direct reflection of the effectiveness 
of inoculations, immunity and treatment in humans.  Some of the challenges 
imposed by this method are that the results can be affected by environmental 
control factors and the accuracy depends on the technical efforts of the 
microscopy, which can be inconsistent when comparing a variety of regions [68, 
69].  The API looks at the number of parasite infections within a defined 
geographical area (typically 1000 persons per year).  This method is considered 
a direct reflection of all the prevention and control effects on humans, but 
depends on active case detection data that often can be poor.  SR looks at the 
proportion of children 2-9 year of age that have a palpable spleen.  This is a non-
invasive way of measuring the impact of malaria on the spleen.  However, there 
are many causes of splenomegaly that complicate interpretation.  Additionally, 
rapid changes in point prevalence, and variability in examiner techniques, has 
also been an issue contributing to inconsistencies in this method of reporting 
[70]. 
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Pathogenesis 
Manifestation of malaria’s clinical symptoms can range from mild to severe 
and even death, although it is curable if diagnosed and treated promptly.  Most 
infections of adults living in endemic areas are clinically silent due to adaptive 
immunity, that is able to prevent disease, while the more clinically overt cases 
occur in non-immune individuals [71].  Two major factors influencing the 
progression of disease is the age and immune status of the infected individual.  
In the endemic regions of Africa, the major burden of malaria is in children under 
the age of five and pregnant women [12, 38].  Due to this threat, the fight against 
malaria has employed a multifaceted approach to reduce infection in these at-risk 
populations. 
The pathogenesis of malaria is a complicated process modulated by both 
parasite and host factors allowing it to successfully propagate in the various 
environments of their hosts.  One such mechanism is the ability to express 
variant surface antigens such as P. falciparum erythrocyte membrane protein 1 
(PfEMP-1) that allows the infected red blood cells (RBCs) to bind to vascular 
receptors preventing splenic clearance [72, 73].  The challenge posed by 
immune recognition via this surface protein is circumvented by antigenic variation 
[38, 71, 74].  However, development of cross-reactive antibodies to 
subpopulations of variant antigens has been found to produce semi-protective 
immunity [74, 75].  Unfortunately multiple gaps still remain in the most effective 
strategies leaving solutions to this challenge out of our reach [76].  
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During development in RBCs several toxic byproducts of metabolism 
including hemozoin, accumulate in the infected cell.  When the RBC lyses to 
release invasive merozoites, toxic byproducts stimulate macrophages to release 
cytokines producing acute inflammatory responses [77].  Typically, these 
infections are divided into two categories; uncomplicated and complicated (or 
severe) malaria.  Uncomplicated cases commonly present a combination of 
fever, chills, sweats, headaches, nausea, body aches and general malaise [13, 
14].  These symptoms can sometimes be associated with other illnesses, such 
as a common cold or influenza, however when recognized as malaria, residents 
in areas with frequent malaria infection tend to seek diagnostic confirmation or 
treat themselves [38, 78].  Diagnosis depends on the observation of parasites in 
the blood by microscopy, while other diagnostic observations may include a 
decrease in blood platelets or elevation in bilirubin and aminotransferases [77].  
More serious symptoms can occur in severe malaria which is accompanied by 
organ failures and abnormalities in the patient’s blood and metabolism [79, 80].  
Additionally, cerebral malaria and anemia are common occurrences as well as 
low blood pressure, respiratory acidosis, and hypoglycemia [38, 74].  Recovery 
from infections of P. vivax and P. ovale are sometimes followed by relapses due 
to hypnozoites that can lay dormant in the liver for several weeks, months, or 
even years [31, 81].    
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Plasmodium Life Cycle 
The life cycle of Plasmodium depends on the infection of two distinct 
hosts, a mosquito and a vertebrate (Figure 1.4).  Asexual development in the 
vertebrate host is comprised of an initial single round of exo-erythrocytic 
schizogony in infected liver hepatocytes followed by potentially unlimited rounds 
of intraerythrocytic schizogony.  The intraerythrocytic stage of development (48 
hour cycle) is the underlying cause of malaria.  A product of intraerythrocytic 
development is macro- and microgametocytes, which are ingested by mosquitos 
when obtaining a blood meal. 
Mosquito (Definitive Host) 
Transmission of the malaria parasite from person to person occurs 
through the bite of the female Anopheles mosquito.  There are approximately 
3500 species of mosquitos, of which, 430 are Anopheles [77].  Their geographic 
range covers most global regions with the exception of the Antarctic (Figure 1.5) 
[82].  Of the known Anopheles, 40 to 50 of these species are capable of 
transmitting malaria and the ability of a given species to transmit malaria is 
dependent on the region and environment.  Since their range is not limited to 
endemic regions, and includes areas where malaria has been eliminated, there is 
always a looming risk of re-introduction [83].  Efforts have been made to 
understand the behavior of mosquitos in an attempt to develop deeper insights 
into the methods of malaria transmission.  Some key factors that facilitate 
mosquito transmission are the choice of host, life span, and susceptibility to 
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Plasmodium.  Female mosquitos have a life span that can extend up to a month 
while the males will live for approximately one week.  Both male and female 
mosquitos feed on nectar as an energy source, however, only the female 
requires blood for the production of eggs [77].  Following ingestion of 
gametocytes, the process of sporogony is activated by a combination of a 5 ºC 
drop in temperature and the gametocyte activating factor xanthurenic acid which 
stimulates the final maturation of the gametocytes to form gametes [84].  This 
process is followed by fusion of the gametes to form a motile oökinete that 
travels by intracellular migration through the midgut epithelium towards the BL.  
The oökinete differentiates to an oöcyst and matures for approximately 10-15 
days before releasing thousands of sporozoites.  The sporozoites then migrate to 
the salivary glands and are injected into the vertebrate host when the mosquito 
feeds.  
Human (Intermediate Host)  
Humans become infected when mosquitos feed, injecting sporozoites into 
skin around the bite area.  During the feeding process, a single infected mosquito 
can inject anywhere from 1-1297 sporozoites, although infection can occur with 
as few as five [85, 86].  Sporozoites can remain in the skin for several hours 
before migrating out into the blood vessels.  Additionally up to 20% of the 
sporozoite inoculum can enter the lymphatic system [87, 88].  Upon entering the 
blood vessels, some sporozoites eventually arrive at the liver where they traverse 
Küpffer cells prior to invading hepatocytes [14].  Development in the liver 
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hepatocytes produces large packages of merozoites (merosomes), which are 
released from the liver into the bloodstream [14, 89].  Each merozoite invades a 
RBC where they produce several invasive merozoites [13, 90, 91].  Lysis of the 
RBC releases the merozoites that invade more uninfected RBCs.  Continuation 
of this cyclical process in the blood results in the fever and chills commonly 
associated with malaria.  In a process branching from this cycle, some of the 
merozoites develop into gametocytes which are the stage ingested by the 
mosquito during blood feeding. 
 Antimalarials 
Over the years, numerous effective antimalarial drugs have been 
developed, however these efforts have been threatened by emerging resistance.  
With the decreasing effectiveness of some of the more common frontline drugs 
such as chloroquine, atovaquone, sulfadoxine-pyrimethamine and mefloquine, 
the effort to develop new drugs has been intensified [36, 40, 92-98].  
Furthermore, recent emergence of artemisinin resistance has increased the 
urgency of this effort [36, 40, 99, 100].  Notably, resistance to a certain 
compound is manifest throughout the entire chemotype class, so efforts cannot 
simply focus on modifying current drugs but rather aim to find new 
pharmacophores as platforms for new malaria therapy [100-102]. 
Endoperoxides 
The endoperoxides are comprised of artemisinin and its derivatives.  
Artemisinin is extracted from the annual wormwood Artemisia annua and has 
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been used in traditional Chinese medicine for more than 2000 years in the 
treatment of febrile illnesses [40].  Since its introduction and use in several 
African and Asian countries the burden of malaria has successfully been 
reduced.  Use of these drugs as artemisinin combination therapies (ACTs), 
combining two or more antimalarials with different modes of action together, is 
encouraged due to the potential emergence of drug resistance in areas of high 
drug pressure [103].  Though a consensus has not been reached on the 
mechanism of action, the antimalarial activity is thought to arise from the 
peroxide bridge present in all the compounds [64, 104]. Endoperoxides have 
been safe and active against a wide range of Plasmodium stages including 
immature and developing gametocytes [105]. 
Derivatives that are used in combination therapies vary in their activity 
profiles and have been utilized in diverse situations.  Dihydroartemisinin (DHA) 
has been used in combination with piperaquine, and registered for distribution 
under the name Artekin™ [93].  It has been very effective and was evaluated in 
clinical trials in Thailand, Vietnam, Cambodia, and China [106].  Derivatives of 
DHA are artemether, artesunate and artemotil.  These derivatives have better 
biavailability than artemisinin and are used as a once or twice a day dosing 
regimen which is effective at reducing parasite biomass by four orders of 
magnitude over a 48 hour period [36].  Artemether is used for the treatment of 
severe malaria and in combination with lumefantrine for the treatment of 
uncomplicated P. falciparum malaria.  Artemether-lumefantrine is taken as a six-
dose regimen and has been highly effective against multidrug resistant P. 
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falciparum [107-109].  Following the 1999 registration of the drug in Switzerland, 
resulting from a collaboration of Novartis and the Chinese developers, it was 
dually branded and marketed as Riamet® in developed non-endemic countries 
and as Coartem® in malaria endemic countries [106].  Artesunate is the treatment 
of choice for severe malaria and has been used in combination with 
amodiaquine, mefloquine and pyronaridine [36, 106].  Artesunate-mefloquine has 
been widely used in South East Asia and is effective against multidrug resistant 
P. falciparum.  Artesunate-amodiaquine has variable effectiveness and is 
acceptable for use in areas where amodiaquine resistance is low.  Artesunate-
pyronidine has been used for the treatment of malaria since the 1980s and has 
been effective against malaria in Africa, but less effective in Thailand [106].  
Artemisone is a promising second-generation derivative with a longer half-life, 
lower curative dose, greater bioavailabily compared to the other derivatives, and 
did not display neurotoxicity in preclinical testing [105, 110].  Another 
endoperoxide drug, the synthetic peroxide OZ439, was designed to provide a 
single dose oral cure in humans.  It is fast acting against all asexual erythrocytic 
stages of P. falciparum [104].  The peroxide, OZ277 was the first synthetic 
ozonide to be evaluated clinically as a combination therapy with piperaquine 
phosphate.  It exhibits activity against all asexual development stages and is 
currently in Phase III trials [104, 111]. 
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Quinolines 
The quinolines target heme polymerization in the erythrocytic stages of 
Plasmodium development.  Blocking this process promotes the accumulation of 
toxic free heme that eventually leads to the death of the parasite [38, 95, 112-
114].  Two subgroups of these compounds, the 4-aminoquinolines and the 8-
aminoquinolines differ in the position of the amine group. 
4-Aminoquinolines 
Compounds within this group have been effective against erythrocytic and 
sexual stages of Plasmodium in vivo and in vitro.  These compounds have a 
history of being safe and economical, but emerging drug resistance has 
increased the need for alternative analogues [95, 98].  Chloroquine (CQ) is one 
of the most widely used drugs for treating malaria.  It was mainly affective against 
erythrocytic stages of each of the human strains of Plasmodium and 
gametocytes of P. vivax [95].  Emerging resistance in P. vivax to CQ is beginning 
to limit its effectiveness, but it is still effective in most P. vivax endemic areas.  
Hydroxychloroquine is a variation of CQ with a hydroxyl group added to the side-
chain.  The activity and mechanism is similar to CQ and it is prescribed to treat 
the same types of infections [64].  Amodiaquine has been in use for more than 40 
years, and is similar to CQ in both structure and activity [101].  This drug has 
been useful due to its effectiveness against some CQ resistant strains [115].  
Another drug, naphthoquine, is effective against schizonts when used as a 
monotherapy [116].  Though naphthoquine has proven effective against some 
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CQ resistant strains, other recent applications combine it with artemisinin [96, 
107, 116, 117].  Piperaquine is an orally active option that is more effective than 
CQ against P. falciparum [106].  It was first synthesized in the 1960s in China 
and has been just as effective as CQ against P. falciparum and P. vivax.  This 
drug has also been combined with DHA, and following approval by the European 
Commission in 2011, it was marketed as Euratesim®.  This ACT is administered 
once a day for 3 days, and provides longer protection against new infections than 
other ACTs [93, 109, 118, 119].  Pyronidine, in combination with artesunate is 
administered in a similar 3-day fixed-dose regimen.  As a monotherapy, 
pyronidine is effective against drug-resistant P. falciparum malaria, and is also 
used on combination with arteminins [120].  Tert-butyl isoquine was developed 
as a drug candidate as part of a public-private partnership and demonstrates 
excellent activity against P. falciparum both in vitro and in vivo.  It is still under 
investigation as a potential future antimalarial [121].  Amodiaquine-13 is another 
analogue of CQ that is active against CQ-resistant strains [122].   
8-Aminoquinolines 
One of the most commonly used drugs within this group is primaquine, 
which is effective against gametocytes with low activity against erythrocytic 
stages, and is the only drug that can clear dormant (hypnozoite) liver stage 
infections of P. vivax [113, 123].  Monotherapy using primaquine has been 
permitted in some endemic regions and it is also recommended as a follow-up 
treatment to ACTs [38].  A variation of primaquine, diethylprimaquine is effective 
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preventing exflagellation, however, its activity is similar to another derivative 
bulaquine with lower efficacy than primaquine against drug resistant strains [64].  
Tafenoquine is also effective against hypnozoites and can be taken as a 2-3 day 
treatment course [124].  However, use of these drugs has been known to be 
associated with increased risks of hemolysis in glucose-6-phosphate 
dehydrogenase (G6PD) deficient patients [81].  This is due to the formation of a 
reactive quinone imine and peroxy radical that would be toxic in the absence of 
G6PD [38].  Due to its major toxicity in humans, development of NPC-1161B 
provided a new lead compound, which has reduced hematological toxicity and 
promising efficacy against P. vivax [124, 125]. 
Antifolates 
Development of antimalarials from this group was based on the 
understanding of folate derivatives in humans [126].  In the early 1930s folic acid 
was identified as a factor able to reverse some forms of anemia.  Later, 
development of antifolate agents was carried out to treat leukemia.  All the 
antifolates have a greater affinity to P. falciparum dihydrofolate reductase 
(PfDHFR), accounting for the favorable therapeutic index [126].  One study 
suggested that the difference in affinity is due to the different methods of 
regulation where the parasite form is less readily replenished when targeted by 
inhibitors [3].  However, the hypothesis requires further investigation since it 
could not be confirmed in a subsequent study [127].  For the treatment of 
malaria, this group is subdivided into two categories, class I (dihydropteroate 
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synthase inhibitors) and class II (dihydrofolate reductase inhibitors) antifolates, 
and when used in combination, both classes work synergistically in treating 
malaria infections [126].  Proguanil was the first antifolate developed in 1945, and 
was found to be more effective than quinine in animal models [126, 128].  It also 
has a derivative cycloguanil, which has been effective in treating cases of drug 
resistant infections [129].  Proguanil has been used both as a monotherapy, and 
more recently, in combination with atovaquone (Malarone®), as a prophylactic, to 
inhibit electron transport to the cytochrome bc1 complex [126, 130].  There is 
also a chlorinated variant of proguanil, chlorproguanil, that is used less 
frequently.  Due to higher potency, chlorproguanil is recommended as a 
prophylactic at a lower dose.  It was developed through a collaboration of 
GlaxoSmithKline (GSK), Liverpool University and WHO/TDR in East Africa, and 
is more effective than sulfadoxine-pyrimethamine [106].  When used in 
combination with Dapsone (LapDap), chlorproguanil was found to be more potent 
and retain activity against sulfadoxin-pyrimethamine resistant strains [97, 126, 
131-133].  Pyrimethamine (Daraprim®) was identified when antifolate analogues 
were being tested in the treatment of tumors.  Because of a structure similar to 
that of proguanil, pyrimethamine was hypothesized to have antimalarial activity 
and was later screened against the parasites [134, 135].  In practice it is mostly 
used in combination with sulfadoxine with limited use as a monotherapy [126].  
Eventual emerging resistance to antifolates prompted the development of 
additional effective compounds, and this led to development of P218 that was 
deemed suitable for initial studies in humans [136]. 
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Sulfonamides 
Sulfonamides, also known as sulfa drugs, completely inhibit folic acid 
synthesis in microorganisms.  As class I antifolate inhibitors, these compounds 
block dihydropteroate synthase.  Low efficacy and toxicity discouraged their use 
as monotherapy, but interest in this group was maintained due to synergistic 
effects when combined with anti-DHFR compounds.  Dapsone, in addition to 
being combined with chlorproguanil, has also been combined with pyrimethamine 
(Maloprim®).  Pyrimethamine is also combined with sulfadoxine (Fansidar®), 
sulphalene (Metakelfin®) as well as sulfamethoxazole and sulfadiazine [137-
139]. 
Amino Alcohols 
Amino alcohols are widely used in combination with artemisinin derivatives 
and have been affective against resistant parasite strains.  One of the prominent 
amino alcohols lumefantrine is typically administered in combination with 
artemether (Coartem®) [36, 140]. 
Kinases and Phosphatases of Plasmodium  
Bioinformatic characterization of PF13_0027 in PlasmoDB identifies it as a 
putative phosphatase due to presence of a conserved DUSP.  Tandem 
arrangement of the DUSP and the RHD suggest that it is homologous with a 
class of phosphatases known as MKPs that are typically characterized with a 
similar domain arrangement.  The unique phenotype resulting from the disruption 
of PF13_0027’s open reading frame led us to investigate the P. falciparum 
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pathways involving proteins with similar characteristics.  Interestingly, the MAPK 
signal transduction pathway is a well characterized pathway in several 
eukaryotes responsible for multiple intracellular processes when disrupted might 
result in an attenuated phenotype similar to the one observed in the C9 mutant 
parasite.  Functions affected by MAPK pathways are typically utilized to regulate 
critical cellular process such as stress response, osmoregulation, cell cycle 
regulation, signal transduction, or transcription factor interaction (Figure 1.4) 
[141-145].  It is our current understanding that in P. falciparum these pathways 
could be utilized in a similar fashion [146-154].  It is likely that the phenotype of 
C9 parasites results from disrupting one or more of these pathways, however 
further investigation would be necessary to confirm this assertion.  Furthermore, 
since protein phosphatases are integral to cell survival, this putative phosphatase 
provided a novel subject for investigation.  Therefore, my hypothesis is that 
PF13_0027 functions as an important component of intraerythrocytic 
development.   
Protein kinases occupy an important role in eukaryotic cell development 
by regulating the activity of various proteins through additive phosphorylation.  
Phosphatases serve an antagonistic function, removing phosphate groups, 
throughout cellular development and response to external stimuli, which when 
knocked out, can result in aberrant or deleterious effects on development.  
Phosphorylation cascades have become the focus of many studies in 
Plasmodium because of their deduced importance for development.  Much of the 
literature investigates their involvement in cascades regulating the progression 
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from gametocyte to the formation of the zygote and oöcyst in the mosquito 
midgut [142, 154-158].  Given the level of importance that phosphorylation and 
dephosphorylation serve in cellular development, further investigation of this 
process is vital to expanding our knowledge of this malaria parasite’s biology.  In 
studying these pathways it is also important to consider the relationships of both 
kinases and phosphatases.   
Plasmodium Kinases 
Exhaustive evaluation of the kinome in model organisms such as C. 
elegans, D. melanogaster, S. cerevisiae and H. sapiens resulted in the 
identification of 7 groups of protein kinases.  These groups are the cyclic-
nucleotide and calcium/phospholipid-dependent kinases (ACG group); the 
CMGC group, comprised of cyclin-dependent kinases (CDK), mitogen-activated 
kinases (MAPK), glycogen-synthase kinases (GSK) and CDK-like kinases; 
calmodulin-dependent kinases (CamK) group; tyrosine kinases (TyrK) group 
which is absent from Plasmodium; casein kinase 1 (CK1) group; the sterile (STE) 
group, also absent from Plasmodium; and the tyrosine kinase-like (TKL) group 
[159-161].   Another important group to acknowledge in Plasmodium is the 
orphan protein kinases (OPKs) that do not share any homology with mammalian 
kinases and possess atypical enzymes with features from more than one family 
of kinase [162].  
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The ACG Group  
There are five Plasmodium phosphatases from this group; cAMP-
dependent kinase (PfPKA, PFI1685w), cGMP-dependent kinase (PfPKG, 
PF14_0346), PKB-like serine/ threonine kinase (PfPKB, PFL2250c) that 
functions in the phosphoinositide-3-kinase (PI3K)-dependent pathway. Aurora 
related kinase (ARK2, PFC0385c) a putative serine/ threonine kinase involved in 
kinetochore organization, and PF11_0464 a putative serine/ threonine kinase 
[159, 163-165].    
The CMGC Group 
Kinases within the CMGC group [cyclin-dependent kinases (CDK), 
mitogen-activated kinases (MAPK), glycogen-synthase kinases (GSK) and CDK-
like kinases] control cell proliferation and development and in the Plasmodium 
kinome, they make up the most prominent kinase group.  This group includes the 
CDKs which regulate cell-cycle progression, several of which have been 
identified in Plasmodium [162, 166].  These kinases include; PfPK5 
(PF14_0605), PfPK6 (MAL13P1.185), Pfmrk (PF14_0605), Pfcrk-3 (PFD0740w), 
Pfcrk-4 (PFC0755c) and Pfcrk-5 (PFF0750w) [159, 166].  Pfcrk-4 and PfPK6 
both have features of CDKs and MAPKs and form a cluster at an intermediate 
position between both groups in phylogenetic analysis [159].   
The two MAPKs, Pfmap-1 (PF14_0294) and Pfmap-2 (PF11_0147) serve 
a critical function as transducers of intra- and extracellular signals to cell cycle 
control elements and transcription factors [162].  Studies involving the MAPKs 
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have been carried out in both P. falciparum and P. berghei resulting in numerous 
insights into the biology of malaria parasites even though the roles of these two 
MAPKs appear to be reversed in these Plasmodium species.  During 
microgamete formation in P. berghei, MAPKs are involved in control of 
cytokinesis and flagellar motility [152].  Expression profiles in P. berghei have 
shown that Pfmap-2 is not essential to asexual growth and gametocytogenesis, 
but it is essential to microgametogenesis [142].  Contrasting results were 
discovered when investigating MAPK function in P. falciparum when it was 
discovered that Pfmap-2 is critical for asexual development [167].  Furthermore, 
they identified that levels of Pfmap-2 were elevated in Pfmap-1-KO parasites 
suggesting that not only Pfmap-2, but also Pfmap-1 have relevance to asexual 
development.  The CMGC group also has two GSK3-related kinases, PfPK1 
(PF08_0044) and PfGSK3 (PFC0525c), as well as a LAMMER-related kinase 
Clk1 (PF14_0431) [168-170].  The GSKs have a critical function in regulation of 
cell proliferation and the Clks are important for RNA metabolism [162]. 
The CamK Group 
This group occupies an important role in the development of the oökinete 
in the mosquito vector.  Calcium dependent protein kinases (CDPKs) make up a 
family of serine/ threonine kinases found only in protozoa and plants and are 
distinct from all other animal protein kinases [148, 154].  The P. falciparum 
genome encodes 6-7 CDPKs that are developmentally restricted to Ca2+ 
signaling.  This group is characterized by the presence of a kinase catalytic 
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domain located adjacent to four EF-hand calcium binding domains, an overall 
structure that is shared with CDPKs of plants and ciliates [159].  PfCDPKs 1-3 
and 5 (PFB0815w, PFF0520w, PFC0420w and PF13_0211 respectively) are 
expressed throughout the asexual stages while PfCDPK4 (PF07_0072) is 
expressed in the sexual stages [171-174].  PfCDPK4 is essential for the 
development of parasites in the mosquito during male gametocyte exflagellation 
[154, 159].  CPDK4 specifically is one of the kinases responsible for the 
transduction of the Ca2+ signals within the parasite prior to the differentiation of 
the gametocyte to the microgamete.  When CDPK4 is knocked out in P. berghei, 
parasites fail to produce oöcysts supporting the understanding that its expression 
is essential to reproduction [154].  PfCDPK7 (PF11_0242) is similar to the other 
CDPKs with the exception that it contains one EF-hand motif.  An additional 
branch of the CDPK group is PfPK2 (PFL1885c) and PfCDPK6 (PF11_0239) that 
do not have the EF-hand motif [175, 176].        
The CK1 Group 
Plasmodium only has one characterized kinase in this group, PfCK1 
(PF3D7_1136500.1) [159, 177].  Though it is able to phosphorylate several 
proteins in vitro, the role of has not been determined [162].   
The TKL Group   
In this group, of the four malarial enzymes, three kinases, PfTKL4 
(PFF1145c) and PfTKL1 (PFB0520w), and PfTKL2 (PF11_0220) share 
homology with MAPKKK-related enzymes [159, 161, 178].  PfTKL3 (PF13_0258) 
 23 
 
has a sterile α-motif (SAM) domain dependent kinase expressed in both asexual 
development and gametogenesis and is being studied as a viable drug target 
[178]. 
The OPK Group 
The NIMA-related kinases (Nek) family is responsible for centrosome 
replication during eukaryotic cell division [162, 179].  Pfnek-1 (PFL1370w), which 
has been shown to phosphorylate Pfmap-2, is predominantly expressed in both 
the asexual and sexual stages.  Interestingly, the P. berghei ortholog of Pfnek-1 
is only expressed in the microgametocyte which is consistent with the suggestion 
that Pfnek-1 is important for male gametogenesis [162, 180, 181].  The 
remaining, Pfnek 2-4 (PFE1290w, PFL0080c, and MAL7P1.100 respectively) are 
expressed in gametocytes [162, 182].  Studies with the Pfnek-4 ortholog in P. 
berghei have revealed that Pbnek-4 is essential for oökinete maturation, 
revealing another possible role of the Neks [183]. 
Plasmodium Phosphatases 
Phosphatases dephosphorylate proteins reversing and controlling the 
actions of protein kinases.  This function is critical to cell viability since 
unregulated kinase activity can have detrimental effects [184].  Earlier research 
had characterized two main functional groups of protein phosphatases; protein 
tyrosine phosphatases (PTP) that are typically membrane associated and protein 
serine/threonine phosphatases (PP) that are cytosolic [185, 186].  The members 
of these phosphatase families have high sequence conservation within the active 
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site and participate in regulation of cell cycle progression, protein synthesis, 
carbohydrate metabolism, transcription, and neuronal signaling in eukaryotic 
cells which underscores their importance to survival [185].  Furthermore, within 
the PPs, there are two distinct sub-families; Mg2+-dependent phosphatases 
(PPM) and Mg2+-independent phosphatases (PPP) [186]. This group is 
subsequently divided into more specific groups, PP1 (PF14_0142), PP2A, PP2B 
and PP2C.  With respect to PP2C, studies carried out in Toxoplasma gondii 
determined it to have a significant effect on the host cell following invasion [187].  
One study revealed this using GFP fusion tags to localize PP2C and determine 
that the nuclei of host cells were the targets, and that the protein was being 
released from the bulbous region of the rhoptries of the invading parasites [188].  
In recent years, advances in our understanding of phosphatases have led to the 
identification of additional classifications.  Within the genome of Plasmodium, 
four groups of phosphatases are represented: The PPP group; the PPM group; 
the PTP group; and the NLI-interacting factor like (NIF) group (Table 1.1) [2].    
The PPP group 
The phosphatases of this group are highly conserved and among the most 
extensively studied type of protein phosphatases [189, 190].  These enzymes 
target a large variety of substrates that are not limited to phosphoproteins, since 
they are similar to the metallophosphatases in their dependency on Mn2+, Ca2+, 
and/ or Co2+.  Classification of subgroups has been recently extended to include 
as many as eight distinct subtypes of serine/threonine phosphatases (PP1, 
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PP2A, PP2B, PP4, PP5, PP6, PP7 and BSU (plant-specific) [191, 192].  There 
are also three conserved motifs that have been considered as the signature motif 
of the PPP family (GDXHG, GDXXDRG and GNH [E/D]) [191-194].  
Within Plasmodium, several PPs have been identified.  PF3D7_1466100 
(BSU subfamily) is a PP1-related enzyme with closely related orthologs in plants 
encoding Kelch motifs in the N-terminal domain.  These Kelch motifs form distinct 
tertiary structures that are thought interact with regulatory subunits [195, 196].  
Another such phosphatase, PF14_0142 (PP1 subgroup), is expressed in all 
stages of the developmental cycle with a slight reduction during the late 
trophozoite stage [2].  PF14_0224 (PP7 subgroup) has metal (Mn2+) and 
phosphate and water binding motifs, except there are substantial differences 
from the other phosphatase subgroups.  PFC0595c, similar to the PP2/4/6 type 
phosphatases, is expressed with a similar profile; however, microarray data 
suggests additional activity in the sexual stages [182, 197].  PF08_0129 shares 
characteristics with the PP3, PP2B and calcineurin subgroups.  It is 
characterized as a calcineurin-type enzyme with a calmodulin-binding domain.  
PFI1245c is part of the PP2 subfamily and is homologous to the mammalian 
phosphatase PP2A.  These phosphatases are asparate-rich proteins with the 
ability to inhibit the phosphatase PFI1245c.  Subgroup PP5 phosphatases are 
represented in the Plasmodium phosphatome by MAL13P1.274 that contains a 
nuclear targeting sequence in the N-terminus as well as TPR (tetratricopeptide) 
repeats [2].  Phylogenetic analysis of PFI1360c identifies it as closely related to 
the PP2/4/6 subgroups.  Previous data has suggested that it may be involved in 
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centrosome maturation, spliceosome assembly, chromatin modification and 
regulation of the NF-κB and mTOR signaling pathways [2, 193].                  
The PPM Group 
This group is made up of a diverse set of enzymes with Mg2+ and Mn2+ 
dependent phosphatase activity that typically function in modulating stress 
responses.  They typically have regulatory domains in the N- or C-terminal 
extensions [2].  Despite structural similarities between this group and the PPP 
group, they do not share sequence homology [198, 199].  Also a PP2C-type 
phosphatase PF11_0396 has been reported for Plasmodium in literature 
suggesting that it regulates translation factor 1B [2, 187].  Two other PPM-related 
phosphatases are PFE1010w and MAL8P1.109, but they do not have any 
experimental data to support a suggested function.    
The PTP group 
The group is subdivided into three main subfamilies; the PTPs, the 
DUSPs, and the low molecular weight phosphatases [200-204].  Eukaryotic 
phosphatases of the PTP and DUSP subgroups are required for signaling, cell 
growth, differentiation and control of the cell cycle [205].  Since the P. falciparum 
cell cycle is also driven by sequential activation of CDKs [146], the phosphatase 
CDC25 is an essential regulator of the cell cycle that works by activating the 
CDKs through dephosphorylation at the G2-M transition [151, 206, 207].  In 
contrast, humans have three CDC25s (CDC25A, CDC25B and CDC25C) that 
dephosphoryate the threonine and tyrosine residues in order to trigger activation 
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of CDK/cyclin activity.  The CDC25 phosphatases form a distinct group which 
has little sequence similarity with the other PTPs except for the signature motif.  
They appear to have evolved from RHDs that have been known to catalyze 
sulfur-transferase reactions [147].  These types of phosphatases are essential for 
differentiation of the gametocyte to the microgamete since this transition is 
dependent on the three rounds of division that producing eight motile 
microgametes [208].  The microgametes, when fused with the macrogamete, 
form the zygote that further differentiates to the oökinete, which migrates through 
the midgut wall [152].   
The conserved catalytic mechanism of these enzymes is mediated by 
cysteine, arginine and aspartic acid residues comprising the Cx5R signature 
motif [2].  Within P. falciparum some PTPs have been investigated biochemically 
[209, 210].  The first PFC0380w (YVH1) contains a Zn2+-binding domain, 
exhibiting activity against phosphorylated serine and threonine residues.  The 
second, PF11_0139 (PRL, “Protein of Regerating Liver”)) is a protein tyrosine 
phosphatase with the CaaX motif in the C-terminal motif used for farnesylation.  It 
has also been identified as a target of farnesyl-transferase.  In merozoites, it co-
localizes with AMA-1 and may be involved in invasion [2, 210].  Within this group, 
the phosphatase MAL13P1.168, which as similar structure to the PTP family, is 
characterized as having a PTP-like motif.  The catalytic site contains a 
substitution of a proline in place of arginine in the catalytic site [2, 211].  Similar 
to this substitution, PF13_0027 has an isoleucine substitution in place of the 
conserved arginine in the catalytic site.    
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The NIF group 
Phosphatases in this group are responsible for the dephosphorylation of 
the carboxy-terminal domain of RNA polymerase II.  These phosphatases are 
also known to interact with the transcription factor TFIIF.  They are believed to 
dephosphorylate serine in the C-terminal to reactivate the polymerase after 
transcription termination [212-216].  P. falciparum has four identified genes within 
this group.  The NIF phosphatases have a distinct DxDx(T/V) motif in the active 
site that is conserved in two of the sequences, PFE0795c, and MAL13P1.275.  
The third sequence PF10_0124 is closely related, but does not have the intact 
motif, and therefore is considered to be inactive based on preliminary 
bioinformatics analysis.  The fourth sequence PF07_0110 falls within a distinct 
clade of NIF-type domains with a disrupted DxDx(T/V) motif (Table 1.2) [2]. 
Focus of Study 
This dissertation research project investigates the involvement of 
PF13_0027 during intraerythrocytic development of P. falciparum.  PF13_0027 
has a DUSP domain that maintains structural homology to DUSP domains and it 
is conserved across Plasmodium spp. with orthologs in other species (Table 1.3).   
Attenuation of blood-stage parasite growth following functional knockout 
suggests that it has an important regulatory mechanism in the developmental 
cycle, specifically during the late trophozoite when it is maximally expressed.   
Phosphatases have been the focus of several recent drug development 
studies and it is reasonable to investigate this as a novel target since new 
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mechanisms of action for antimalarial drugs are a critical priority.  This priority is 
emphasized by decreased drug efficacy due to increasing drug resistance.  It has 
also been demonstrated that cascades involving protein phosphorylation are 
required for with successful development of Plasmodium parasites as well as 
eukaryotic cells.  Expansion of our knowledge of Plasmodium biology through the 
study of PF13_0027 will augment our understanding of the regulatory processes 
used by these parasites. 
In addition to partially characterizing the function of PF13_0027, this 
phosphatase was also evaluated as a possible drug target through high-
throughput in silico techniques.  Utilizing the available compound libraries in the 
ChEMBL-NTD, we were able to screen a preliminary model of PF13_0027 
against compounds with antimalarial activity and determine if any of these 
compounds interact with the predicted active site.  Several compounds were 
identified and obtained for further in vitro assays and assessed for their effect on 
the asexual cycle.  Through this study we investigate the role of PF13_0027 in P. 
falciparum and suggest a function explaining its contribution to parasite 
development and evaluate it as a drug target. 
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Figure 1.1: The piggyBac transposon mutagenesis system [9].  (A) The 
helper plasmid carries a selectable marker for human dihydrofolate reductase 
(hDHFR) under the control of a 5' calmodulin promoter and 3' calmodulin 
terminator.  (B) The helper plasmid codes for the piggyBac transposase 
which excises the selectable marker allowing it to randomly insert into the 
genome.  (C) Late stage parasites are separated from mixed cultures using a 
magnetic column and mixed with red blood cells (RBCs) containing the 
transposon and helper plasmids.  Transfected parasites are then selected by 
applying drug pressure and cloned to identify parasites with single insertions. 
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Figure 1.2: The spatial distribution of P. falciparum malaria endemicity in 
2010 [7]. 
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Figure 1.3: The spatial distribution of P. vivax malaria endemicity in 2010 [6]. 
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Figure 1.4: Life cycle of the malaria parasite [5]. 
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Figure 1.5: A global map of dominant malaria vector species [4]. 
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Figure 1.6: Summary of the MAPK pathway.  
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Table 1.1: Classifications of phosphatases [1-3]. 
.  
Subgroup Examples 
Signature 
motif 
Metal ions Function 
Phosphoprotein 
phosphatases (PPP, 
PPM, PP2C) 
Metallophosphatases 
GDxHG, 
GDx2GRD 
GNH[E/D] 
Mn
2+
, Mg
2+
, Ca
2+
, Co
2+
 
Modulate stress responses (ex. 
PP1, PP2A, PP2B, PP4, PP5, 
PP6, PP7, BSU) 
Protein Tyrosine 
Phosphatases (PTP, 
DUSP) 
Tyrosine specific and 
dual specificity 
phosphatases 
DXnCX5R - 
Cell cycle regulation and signal 
transduction (ex. Cdc25, MKP) 
NLI interacting factor-like 
phosphatase (NIF)  
TFIIF-associating C-
terminal domain 
phosphatase 1 and Small 
CTD phosphatases 
DxDx(T/V) - 
Interaction with transcription 
factor TFIIF, dephosphorylation 
of the carboxy domain of RNA 
polymerase II 
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Table 1.2: Phosphatases identified in P. falciparum 
ID Annotation 
PPP group (Phospho-Protein Phosphatases) 
PF14_0630 Protein serine/threonine phosphatase 
PF14_0142 Serine/threonine protein phosphatase, putative 
PF14_0224 PP1-like protein serine/threonine phosphatase 
PF10_0320a Protein phosphatase 1 regulatory subunit 7 
PFC0595c Serine/threonine protein phosphatase, putative 
PF10_0177 Erythrocyte membrane-associated antigen HT; SP; API  
PF08_0129 Protein phosphatase, putative 
PFI1245c Protein phosphatase-beta 
PFI1360c Serine/threonine protein phosphatase, putative 
MAL13P1.274 Serine/threonine protein phosphatase pfPp5 
PF13_0222 RNA lariat debranching enzyme, putative  
PFL0980w RNA lariat debranching enzyme, putative  
PFA0390w DNA repair exonuclease, putative 
PF14_0064 Vacuolar protein sorting 29, putative  
PF14_0036 Acid phosphatase, putative 
PF14_0282  Acid phosphatase, putative 
PF14_0660 Hypothetical protein; Protein phosphatase (PPP group, Shelphs bacterial-
like subgroup), putative SP; API 
PFL0300c Phosphoesterase, putative SP 
PF14_0614 Hypothetical protein; metallo-dependent phosphatase SP  
PF10_0177a Serine/threonine protein phosphatase, putative  
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Table 1.2: Continued 
ID Annotation 
PPM group (Mn
2+
 or Mg
2+
 dependent protein serine/threonine phosphatases) 
MAL13P1.44 Protein phosphatase 2c-like protein, putative 
PFL2365w Hypothetical protein, conserved; Protein phosphatase (PP2C/PPM group), 
putative 
PF14_0523 Protein phosphatase 2C, putative 
PFD0505c Protein phosphatase 2C 
PFE1010w Protein phosphatase 2c, putative 
PF11_0362 Protein phosphatase, putative 
PF11_0396 Protein phosphatase 2C 
MAL8P1.109 Protein phosphatase 2C, putative 
PFL0445w Conserved Plasmodium protein, unknown function; protein phosphatase 
PF10_0093 Protein phosphatase, putative  
MAL8P1.108 Protein phosphatase, putative 
PF10_0093 Hypothetical protein; Protein phosphatase (PP2C/PPM group), putative 
  
PTP group (Protein Tyrosine Phosphatases) 
PF14_0524 Protein phosphatase 7 homolog, putative API 
PFC0380w Dual-specificity protein phosphatase, putative 
PF11_0139 Protein tyrosine phosphatase, putative 
PF11_0281 Hypothetical protein: weak similarity to dual specificity protein phosphatase 
MAL13P1.168 Hypothetical protein, conserved; Protein tyrosine phosphatase 
PF13_0027 Protein phosphatase, putative 
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Table 1.2: Continued 
ID Annotation 
NIF group (NLI  interacting  factor-like  phosphatases) 
PFE0795c Nif-like protein, putative 
PF07_0110 Hypothetical protein, conserved; CTD phosphatase 
PF10_0124 Hypothetical protein; CTD phosphatase 
MAL13P1.275 NLI interacting factor-like phosphatase, putative; CTD phosphatase 
  
Others 
PF14_0492 Protein phosphatase 2b regulatory subunit, putative  
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Table 1.3: Orthologs of PF13_0027 [8]. 
 
Accession Taxon Description 
PBANKA_140400  Plasmodium berghei str. ANKA conserved Plasmodium 
protein, unknown 
function  
PCHAS_140590  Plasmodium chabaudi chabaudi conserved Plasmodium 
protein, unknown 
function  
PFIT_1304700  Plasmodium falciparum IT protein phosphatase, 
putative  
PKH_140400  Plasmodium knowlesi strain H conserved Plasmodium 
protein, unknown 
function  
PVX_122110  Plasmodium vivax SaI-1 hypothetical protein, 
conserved  
PY00561  Plasmodium yoelii yoelii str. 17XNL hypothetical protein  
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Chapter 2:  Identification of a Putative Phosphatase in Plasmodium 
falciparum Regulating Progression from Pre-S Phase Blood Stage 
Development (Specific Aim 1) 
Rationale for Study 
Regulation and developmental checkpoints in blood-stage P. falciparum 
are complex and critical components of malaria transmission.  Regulation of this 
important developmental phase depends on the functions of kinases and 
phosphatases [143, 151, 211, 217-223].  Kinases and phosphatases modulate 
the active-to-inactive state of substrates through phosphorylation-to-
dephosphorylation, respectively.  Much of the current research in Plasmodium 
has focused on mechanisms controlling transcription regulation and cell 
proliferation, as a target for novel antimalarials, directed at the asexual blood-
stage cycle [224].  Other studies have investigated phosphorylation cascades 
during the gametocyte-oökinete-oöcyst transition in the mosquito midgut [154, 
225].  PF13_0027 is conserved in Plasmodium species and expressed 
throughout the intraerythrocitic cycle, suggesting a conserved role throughout 
parasite development.  In this study, we use a PF13_0027 mutant (C9), created 
by disruption of the gene’s ORF during the course of a large-scale transposon 
mutagenesis project of P. falciparum, to evaluate the function and significance 
during intraerythrocytic development.  
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Introduction 
P. falciparum is the most deadly of the five known human malaria parasite 
species.  It causes deaths in the hundreds of thousands each year, and millions 
of clinical illnesses [10].  It is the major cause of severe malaria and grows 
rapidly within the blood of infected individuals through successive cycles of 
asexual growth and proliferation.  Active entry into erythrocytes is followed by a 
pre-S growth phase consuming the host proteins until a switch to S/M 
proliferation and cytokinesis in the last third of the cycle.  This process 
culminates in a dynamic release of erythrocyte-invading merozoites.  The rate of 
growth and extent of proliferation varies among isolates and is implicitly of 
importance for disease progression during an infection.  Other malaria parasites 
of the phylum Apicomplexa, such as T. gondii or Eimeria tenella, share this 
pattern of asexual development suggesting the importance of this pattern of 
development throughout the phylum [226].   
In eukaryotic systems, phosphorylation cascades are critical to cellular 
development and depend on the coordinated activity of kinases, which are in turn 
modulated by the activity of phosphatases.  There is growing evidence that 
kinases are critical regulators of cell growth and development in Plasmodium 
species [227-229]. Plasmodium kinases, for example, have been found to be 
involved with the initial invasion of host cells in addition to egress and 
differentiation [226, 230].  Additional studies have identified kinases in 
phosphorylation cascades of the gametocyte-oökinete-oöcyst transition in the 
mosquito midgut [154, 225, 231-235].  In contrast, few studies have described 
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the phosphatases involved in these processes, which would understandably 
function with kinases to co-regulate cell cycle progression at key checkpoints [2, 
188, 236-238].  This dearth of information about phosphatases may be due to a 
smaller relative number of identifiable phosphatases in the Plasmodium genome 
compared to kinases [2, 239].  However, it is not uncommon for phosphatases to 
be fewer in number due to their non-specific mechanism of targeting 
phosphorylated substrates [240].  
The protein tyrosine phosphatase (PTP) superfamily is defined by a 
conserved CX5R motif located in a phosphate-binding pocket.  Dual-specificity 
phosphatases (DUSPs) are a subset of this superfamily that includes the 
mitogen-activated protein kinase (MAPK) phosphatases (MKPs).  MKPs are 
frequently involved in regulation of cell cycle progression, growth, and 
proliferation [222].  One class of MKP is characterized by the presence of a non-
catalytic N-terminal rhodanese (RHD)-like domain utilized for substrate 
recognition upstream from a catalytic DUSP domain [143, 153, 219].  In P. 
falciparum, PF13_0027 is the only gene encoding a product with these 
characteristics [2].  In this study, we hypothesize that PF13_0027 is an atypical 
MAPK phosphatase of P. falciparum expressed during intraerythrocytic 
development. 
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Materials and Methods 
In vitro Parasite Culture Conditions   
P. falciparum NF54 and mutant C9 clones were cultured according to 
standard methods at 37°C (5% O2 and 5% CO2, nitrogen balanced) in 5% 
hematocrit (O+ blood) and RPMI 1640 medium with and 0.5% Albumax II, 0.25% 
sodium bicarbonate and 0.01 mg/ml gentamicin [241]. The C9 mutant parasite 
line was created by random insertional mutagenesis using the piggyBac 
transposon pXL-BACII-HDGH (Appendix A).  The location of the insertion in the 
PF13_0027 ORF was confirmed by thermal asymmetric interlaced (TAIL) 
sequence analysis. 
Determination of Merozoite Number Per Schizont 
Parasite cultures were synchronized with 5% sorbitol [241].  Merozoite 
numbers were counted in 300 segmented schizonts in Giemsa-stained thin 
smears from NF54 and C9 parasites to determine average number of merozoites 
produced per schizont. 
RNA Extraction and Analysis by qRT-PCR and RT-PCR  
NF54 RNA was collected from six intraerythrocytic developmental stages; 
early rings, late rings, early trophozoites, late trophozoites, early schizonts and 
late schizonts (ER, LR, ET, LT, ES and LS, respectively) followed by saponin 
lysis and suspended in TRIzol® reagent (Life Technologies™), RNA purified, and 
treated with DNase I.  Purity was confirmed by PCR carried out without the 
addition of reverse transcriptase.  PF13_0027 transcripts were amplified using 
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primers 5′-TCGATTTTGAGGAGCTGAA-3′ and 5′-
GGGTAAAACATCCTTTTTGTT-3′ with SuperScript® III Platinum® SYBR® Green 
One-Step qRT-PCR Kit (Life Technologies™) following the manufacturer’s 
protocol.  For RT-PCR analysis, 100 ng DNAse1-treated total RNA was amplified 
using primers 5′-CACCATGGAATATAAAAGCATCGATTTTG-3′ and 5′-
GTTTATGTAATTATTTATTACTATAAATGGTC-3′, and analyzed by horizontal 
agarose gel electrophoresis.     
Plasmid Constructs and Genetic Complementation 
The plasmid was developed with the full-length PF13_0027 ORF and its 
native 5ʹ untranslated region (UTR), a C-terminal hemagglutinin (HA) tag and the 
3ʹ UTR calmodulin (CAM) termination sequence.  For drug selection, the plasmid 
carried a blasticidin S deaminase (BSD) drug selection cassette under control of 
5′UTR of histidine rich protein (HRP3) and 3′ UTR histidine-rich protein-2 
(HRP2).  Mutant variations of PF13_0027 were generated using the 
complementation plasmid by site-directed mutagenesis of the conserved cysteine 
(C383A), aspartic acid (D345A), and the two conserved lysines (K388A and 
K394A). 
Schizonts were isolated from a 20 mL culture with 3-5% parasitemia using 
a VarioMACS™ Separator (Miltenyi Biotec) and counted with a hemacytometer.  
Fresh 50% hematocrit blood was washed and combined with Cytomix [241] in a 
1:1 v/v ratio and aliquot into chilled 2 mm cuvettes, and electroporated using a 
Gene Pulser Xcell CE™ (Bio-Rad) to load RBCs with transposon and helper 
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plasmids purified using methods described previously [9].  Positive transfected 
clones were selected using blasticidin, diluted, then transferred to 96-well culture 
plates and maintained for 17 days to select individual clones.  Clones were 
validated by PCR following transfection and drug selection to verify presence of 
the correct drug selection cassette (Appendix B). 
Growth Assay and Cell Cycle Determination 
Growth assays for cell cycle determination were performed by maintaining 
tightly synchronized cultures of P. falciparum NF54 and C9 clones at 0.5–2% 
parasitemia.  Time points were collected every two hours and then fixed in 0.05% 
glutaraldehyde after removal of culture medium.  Parasitemia was estimated 
using flow cytometry as described previously [242] by staining parasites with 
ethidium bromide and analyzed using an Accuri C6 flow cytometry system (BD 
Accuri™).  A total of 100,000 cells were counted for each sample and the data 
was analyzed using CFlow Plus software (Appendix C) (BD Accuri™).  The cell 
cycle was determined by comparing the relative abundance of each 
developmental stage at each time point according to methods developed 
previously [243].  Relative fold change was determined by calculating the fold 
increase in parasitemia between time zero and the endpoint.  Each sample was 
then plotted as a percent relative to NF54. 
Invasion Assays 
Schizonts were isolated from a 20 mL culture with 3-5% parasitemia using 
a VarioMACS™ Separator (Miltenyi Biotec) and counted with a hemacytometer.  
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Purified late-stage schizonts were used to initiate cultures in 96-well plates in 
triplicate and cultured for 30 hours to allow segmentation and invasion of fresh 
RBCs.  Parasites were fixed and labeled for flow cytometry as stated in the 
growth assay protocol and the fold increase in parasitemia over the 30-hour 
assay was calculated as a representation of the percent of parasites successfully 
invading and continuing through development.   
Multiple alignments and phylogenetic analysis   
The sequence of PF13_0027 and orthologous Plasmodium sequences 
were retrieved from PlasmoDB v9.2 (www.plasmodb.org).  Outlier species were 
identified through BLAST searches with the DUSP domain using NCBI BLASTP.  
Sequences with greatest homology to PF13_0027 were retrieved and used to 
build the multiple alignments using ClustalW [244, 245].  Phylogenetic trees were 
created using the Neighbor-joining method with 1000 bootstrap in MEGA5 [246-
248].  
Southern Blot Hybridization 
Genomic DNA (4 μg) extracted from transformed parasites was digested 
with 10 units of SalI and DraIII (New England Biolabs®) overnight and separated 
on a 0.8% TAE agarose gel.  The DNA was depurinated in 0.25 M HCl, 
denatured in 0.5 M NaOH/1.5 M NaCl, neutralized in 0.02N NaOH, 1M 
C2H3O2NH4 and blotted overnight to a nylon membrane. A 711 bp probe was 
developed against the bsd drug selection cassette using primers 5′-
ATAAGAAGAAGTATATAATGAATTATATATAATGCT-3′ and 5′-
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CATATGTATTTTTTTTGTAATTTCTGTGTTTAT-3′.  The blot was then 
hybridized to 32P-labeled probe washed three times in 2X SSC/0.5% SDS (1X 
SSC/0.15 M NaCl/ 0.015 M NaC6H5O7, pH 7.0) for 15 min, and exposed to a 
Kodak photographic film at -80°C to visualize the hybridized fragments (Appendix 
D). 
Results 
Identification of an Attenuated Growth Mutant in P. falciparum 
A collection of unique mutant clones was created from a laboratory line of 
P. falciparum NF54 using random insertional mutagenesis with a piggyBac (pB) 
transposon [9].  The C9 parasite line carried one copy of a pB transposon (pXL-
BACII-HGDH) inserted near the 5′ end of the single ORF of PF13_0027 (Fig. 
2.1).  Intraerythrocytic growth for clone C9 was analyzed and determined to be 
severely attenuated with a net growth rate consistently 50% of the NF54 parent 
(Fig. 2.2).  During development, intraerythrocytic stages did not demonstrate any 
obvious differences in morphological characteristics (Fig. 2.3), and mean 
numbers of merozoites produced did not vary significantly from the NF54 parent 
(Fig. 2.4).    
Defining Characteristics of PF13_0027 
The protein encoded by PF13_0027 was determined to have two key 
structural features, a RHD domain followed by a DUSP-like domain.  
Bioinformatics analysis defined this tandem arrangement as characteristic of 
certain MKPs conserved within humans and other model organisms such as fruit 
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fly and yeast [145, 221, 249, 250].  It is for this reason that we refer to the 
PF13_0027 product as P. falciparum MKP.  The conserved signature motif of 
CX5R, which is typically definitive of DUSP domains in MKPs, is only partially 
conserved in PF13_0027 (Fig. 2.5A).  The putative binding pocket of PF13_0027 
was identified through BLAST searches and multiple sequence alignments with 
MKPs that have 3-D crystal structures (Plasmodb version 9.2; NCBI GenBank 
Flat files release 193.0).  Within this binding pocket the amino acid residue 
cysteine-383 (C383) along with another residue of the catalytic triad aspartate-
345 (D345) are conserved and align with conserved cysteine and aspartic acid of 
the other identified DUSPs.  However, the third conserved catalytic residue, 
arginine, aligns with isoleucine-398 (I398) in PF13_0027.  During 
dephosphorylation, the conserved arginine is critical for dephosphorylation 
activity, since active DUSP domains often depend on arginine to maintain the 
transition state with the phosphorylated substrate [251].  Absence of arginine is 
expected to drastically reduce the catalytic activity of the DUSP; therefore, this is 
an important departure from the consensus motif defined for catalytically active 
DUSP domain orthologs and would be expected to reduce phosphatase activity 
[251, 252].   
Prior mutagenesis studies and analyses of catalytic domains in the 
DUSPs of model organisms suggest that unique characteristics, such as the 
ones identified in PF13_0027, may be characteristic of a pseudophosphatase or 
a low activity phosphatase [253-255].  Additionally, there is an insertion of nine 
residues disrupting the spacing within the CX5R signature motif.  Though it 
 50 
 
cannot be determined if this insertion changes the three-dimensional structure 
within the putative binding pocket, this unique stretch of residues is conserved in 
each of the Plasmodium orthologs.  Conservation of these unique characteristics 
in Plasmodium species supports the formation of an individual clade (Fig. 2.5B). 
PF13_0027 Regulates Transition from Pre-S phase to S/M Phase 
In wild-type parasites, the highest relative abundance of PF13_0027 
transcripts is at the end of the pre-S development phase (i.e., late trophozoite) 
during intraerythrocytic development [256].  This expression profile coincides with 
the stage when the C9 mutant cycle deviates from the wild-type cell cycle (Fig. 
2.6).  Utilizing the detailed time course experimental protocol developed 
previously [243], the timing for NF54 was determined to be 46 hours compared to 
52 hours in C9 null MKP mutant.  The difference resulted from a prolonged pre-S 
trophozoite stage causing late entry into the S/M schizont phase.  The length of 
schizont development (S/M - C) was similar in C9 and NF54 making pre-S phase 
the only abnormal growth phase of the intraerythrocytic cycle (Fig. 2.7).   
Phenotype Rescue of Wild-type Growth by Genetic Complementation 
Attenuated growth of the C9 MKP null mutant remained stable over 
multiple subsequent generations suggesting that survival was not due to 
phenotype reversion.  This is consistent with general experience using the 
piggyBac system as it is now extensively used in a number of organisms and the 
transposable elements remain integrated in the genome in the absence of 
transposase [9, 257-262].  However, the extended maintenance of P. falciparum 
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intraerythrocytic cultures required for transfection and the selection process in 
the experimental studies increases the possibility for secondary mutations to alter 
the cell cycle or cause growth attenuation.  Therefore, to validate that the 
phenotype was due to disruption of PF13_0027, we genetically complemented 
the C9 mutant with a full-length copy of PF13_0027, including its putative 
promoter region (Fig. 2.8).  The 5′ intergenic region between PF13_0027 and the 
upstream gene MAL13P1.28 was added to the ORF to ensure the native 
promoter was included.  Using the BSD resistance marker on the complement 
vector, we were able to select for two independent cloned lines, E3 and E8.  RT-
PCR analysis of both E3 and E8 revealed that the complemented parasite lines 
transcribed PF13_0027 in contrast to C9 that did not have detectable transcripts 
(Fig. 2.9).  Through the use of whole genome sequencing (Appendix D), 
Southern blot hybridization analysis (Appendix E), and PCR validation (Appendix 
F), it was also determined that the complemented parasite lines maintained the 
full-length copy of PF13_0027 as stable episomes.  Complementation of the C9 
mutant with the full-length copy of PF13_0027 rescued the phenotype of both E3 
and E8 as evident by their return to normal growth (Fig 2.10).  Additionally, the 
invasion phenotype was also restored in complemented parasites as well (Fig. 
2.11).  Results from site-directed mutagenesis confirmed that rescue of the 
phenotype was not achieved in the absence of cysteine or aspartic acid for 
growth (Fig 2.12) or invasion (Fig. 2.13).  Replacement of the conserved lysines 
did not attenuate the phenotype and parasites were complemented as seen with 
the unaltered ORF (Statistical tables in Appendix G).  Considering the roles 
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cysteine and aspartic acid play in the binding and removal of phosphates, it is a 
possibility that these residues are critical to the function of PF13_0027. 
Discussion 
Cell cycle progression, in P. falciparum, and completion of 
intraerythrocytic development is highly dependent on a precise pattern of 
metabolic events.  Disruption of any of the numerous biochemical pathways and 
processes is anticipated to have detrimental effects on the efficiency of this 
process.  In our study, we discovered that normal cell cycle development was 
delayed by disruption of PF13_0027, indicating that this atypical phosphatase is 
a regulator of the P. falciparum cell cycle.  The delayed transition from the pre-S 
trophozoite to the S/M schizont suggests this transition phase during the 
parasite’s intraerythrocytic growth is a cell cycle checkpoint.  Rescuing the 
phenotype in the null mutant through genetic complementation validated the 
attenuated phenotype.   
Considering the attenuated phenotype along with the homology found 
between PF13_0027 and the other well characterized MKPs, it can be suggested 
that this putative atypical phosphatase fulfills a similar function in Plasmodium.  
MKPs of similar structure are often involved in signaling pathways, which could 
be a likely function of PF13_0027 [2, 263].  Investigations in yeast demonstrate 
MKPs are critical components of various signal transduction pathways that 
regulate transcription and maturation, which can also have an influence on the 
cell cycle [145, 250].  Disruption of such functions in P. falciparum could produce 
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the phenotype observed in C9.  This domain structure is not evident in any other 
gene in the P. falciparum genome, but single copy orthologs are evident in all of 
the other Plasmodium species with completed genomes, suggesting its function 
is conserved among all malaria parasites.  The presence of an RHD domain 
upstream of the DUSP is consistent of a secondary regulatory function that aids 
in substrate recognition and activity of MKPs [211, 219, 222].  Conservation of 
this domain in PF13_0027 as determined by bioinformatics analysis implicates 
MAPK-like function for this atypical phosphatase.   
Identification of PF13_0027 as a putative protein phosphatase is likely due 
to the partial conservation of the conserved CX5R signature motif.  Each catalytic 
residue is critical to optimal function of a phosphatase, and the modifications 
suggest that this DUSP may not be highly catalytic or possibly a 
pseudophosphatase.  Non-catalytic pseudophosphatases typically maintain 
structural homology with active phosphatases allowing them to trap 
phosphoproteins, thereby regulating cellular functions without dephosphorylation 
activity [253, 255].  One such DUSP-homology domain in pseudophosphatases 
is referred to as a serine threonine tyrosine interacting (STYX) domain, which 
has an endogenous substitution of one, or more, of the catalytic residues [255, 
264, 265].  Reports of pseudophosphatase activity in Caenorhabditis elegans 
demonstrate this function as an important role fulfilled by Egg-4 and Egg-5 in 
controlling oocyte-to-zygote transition [266].  It has also been proposed that 
physical access of native phosphatases is blocked by these 
pseudophosphatases, which exert a “dominant negative” function, thereby 
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protecting substrates from dephosphorylation [253].  This is not a surprising 
regulatory mechanism considering that the DUSP binding pockets generally lack 
substrate specificity.  Interestingly, the Apicomplexa possess a unique group of 
pseudophosphatase with long N-terminal domains and EF-hand motifs termed 
“EFPPs” [267].  However a grouping of the variety of STYX domain 
pseudophosphatases, which have a substitution of the cysteine residue in the 
CX5R motif, has never been characterized in Plasmodium.  PF13_0027 does not 
have the EF-hand motif or Ca2+ binding sites typically associated with the EFPP 
grouping; however, it is missing the conserved arginine that would make it a 
unique classification of putative protozoan pseudophosphatase.  
The pressing need for new antimalarial drugs and identification of new 
targets is critical due to emerging resistance to frontline drugs and the lack of 
diverse chemotherapeutic targets [36, 268].  Furthermore, there have not been 
any new classes of antimalarial drugs introduced into clinical practice since 1996 
[94, 269, 270].  As a result, the preferred methods for use of antimalarial drugs 
have been combination therapies due to the foreseeable challenges associated 
with monotherapy or highly mutable drug targets [36, 271].  Kinases and other 
regulators of phosphorylation pathways of malaria parasites represent potential 
high value targets for future antimalarial drugs.  However, the complex processes 
of phosphorylation cascades in Plasmodium are poorly understood and limit our 
ability to identify the highest value targets.  Our discovery of PF13_0027 as an 
important regulator of the cell cycle helps elucidate the trophozoite to schizont 
transition stage as a potentially vulnerable step of the developmental cycle and 
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will help create new avenues into understanding Plasmodium biology.  The 
phenotype associated with C9 highlights this pathway and the regulated 
processes as potential targets.  With further delineation of the function of the 
PF13_0027 and identification of its interacting partners, additional knowledge 
arising from its study will aid future drug discovery.  
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Figure 2.1: Growth phenotype of C9 mutant parasite is due to disruption of 
PF13_0027.  A schematic of PF13_0027 disrupted by a single insertion of 
the piggyBac transposon.  Tandem RHD and DUSP domains are 
characteristic of MKPs.  
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Figure 2.2: Growth of mutant C9 parasites as a percent of NF54. 
Calculation of fold change reveals that the knockout of PF13_0027 
resulted in a reduced fold change of 50% relative to NF54.  
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Figure 2.3: Morphologic analysis of the C9 mutant compared to NF54. 
Comparison of Giemsa-stained thin blood smears of the wild-type parent NF54 
and C9 did not reveal an obvious difference in major developmental stages.   
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Figure 2.4: Comparison of merozoites produced per schizont in mutant and wild-
type parasites.  Average merozoite counts in segmented schizonts of NF54 and 
C9 were not statistically different. 
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Figure 2.5: Multiple alignment and phylogenetic analysis of PF13_0027.  (A) 
Alignment of PF13_0027 with its Plasmodium orthologs and outlier species 
showing the conservation of catalytic residues (boxes).  Cysteine and 
aspartic acid align with all homologs.  Isoleucine aligns with the position of 
the conserved arginine and is conserved in all species of Plasmodium.  A 
string of residues (bracket) are inserted into the signature motif and is 
conserved among the Plasmodium orthologs.  (B) Phylogenetic analysis 
using Neighbor-joining method with 1000 bootstrap shows grouping of the 
Plasmodium sequences independent of the other species suggesting an 
early divergence in evolutionary lineage.  
 
 61 
 
    
 
 
Figure 2.6: Transcription profile of PF13_0027.  Analysis by qRT-PCR 
showed that expression of PF13_0027 has its highest expression 
relative to actin during late trophozoite 32 hours post invasion.  This 
stage corresponds to late pre-S development where the cell cycle of 
null mutants deviates from the wild-type development pattern.  
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Figure 2.7: The cell cycle of C9 null MKP mutant is altered.  Cell cycle 
analysis reveals a prolonged pre-S phase in mutant parasite lines.  Late entry 
into the S/M phase leads to an overall longer cycle time producing a slow 
growing phenotype.  The blue, red and green graph lines represent the relative 
abundance of rings, trophozoites and schizonts, respectively.  The pre-S 
phase in NF54 is 26 hours followed by a 16 hour S/M and 2 hour cytokinesis 
(C).  In C9 the cycle time is increased by 6 hours due to the longer 32-hour 
pre-S phase. Late entry into the S/M phase coincides with the timing for peak 
expression of PF13_0027 suggesting that the deficiency in the mutant cycle 
can be correlated to the gene expression pattern.  
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Figure 2.8: Transfection plasmid used for complementation of C9.  The 
plasmid construct used to complement the attenuated C9 parasite line was 
developed using the full-length PF13_0027 ORF inserted adjacent to a BSD 
drug selection cassette.  
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Figure 2.9: RT-PCR analysis of complemented parasites.  Results detected 
PF13_0027 transcripts in NF54 and the complemented parasites (E3, E8), 
but not in C9 null MKP mutant (red arrow).  As a positive control, 18S RNA 
was also included for each sample (blue arrow).   
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Figure 2.10: Genetic complementation of C9 mutant rescues wild-type 
growth.  The growth of the complemented parasites (E3, E8) were graphed 
as a percent of NF54.  Each of the complemented parasite lines were 
statistically the same as wild type NF54 demonstrating successful rescue of 
the phenotype. 
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Figure 2.11: Genetic complementation of C9 mutant rescues wild-type 
invasion.  The invasion phenotype of the complemented parasites (E3, E8) 
were graphed as a percent of NF54.  Each of the complemented parasite 
lines were statistically the same as wild type NF54 demonstrating 
successful rescue of the phenotype. 
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Figure 2.12: Growth phenotype is not rescued when conserved residues 
are mutated.  Mutant constructs of the complementation plasmid were 
developed.  Two single mutants (C383A and D345A respectively) and 
one double mutant (K388A, K394A) were used to complement C9.  The 
phenotype was not rescued with the C383A and D345A constructs, 
however restoration of the wild type phenotype was observed in the 
K388A/ K394A construct suggesting these residues are not as critical to 
the function of PF13_0027.   
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Figure 2.13: Invasion phenotype is not rescued when conserved 
residues are mutated.  The invasion phenotype of the complemented 
parasites with mutations was compared to NF54. The results were 
consistent with the growth assays showing phenotypic rescue in only the 
double lysine mutant.  
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Chapter 3:  Identification of Novel Inhibitory Compounds and Evaluations 
of Plasmodium falciparum Susceptibility (Specific Aim 2) 
Rationale for Study 
As the causative agent of malaria, P. falciparum poses a great threat to 
global health, and the need for effective drugs is a high priority.  Currently, 
emerging resistance to several of the most common antimalarials has intensified 
the need for drugs with novel mechanisms [20, 36, 38, 40].  A potential new 
target is PF13_0027 that was identified through the course of a large-scale 
random insertional mutagenesis project.  In this current study we were able to 
build on this discovery to identify molecular inhibitors from the European 
Molecular Biology Laboratories database of bioactive drug-like small molecules 
for Neglected Tropical Disease (ChEMBL-NTD) through high-throughput in silico 
screening (HTS) with a homology model of the DUSP domain.  The homology 
model of the tertiary structure of PF13_0027 was generated using the resolved 
crystal structure of the human phosphatase MKP3 as a template.  The binding 
pocket was identified readily by a sequence similarity search and multiple 
sequence alignments.  Then the pocket was cross-referenced with results from 
the computed atlas of surface topography of proteins (CASTp) server for 
validation.  In silico high-throughput docking screens identified seven antimalarial 
compounds from ChEMBL-NTD which were selected for functional analysis.  The 
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compounds were evaluated against P. falciparum NF54 for their ability to alter 
the parasite’s cell cycle in a fashion similar to the attenuated C9 mutant.  At least 
one of the compounds extended the normal cell cycle length producing a 
phenotype similar to the C9 attenuated mutant. Through this study we 
demonstrate the potential for the phenotype of a pB mutant to guide identification 
of novel target-specific antimalarials. 
Introduction 
Malaria primarily affects tropical and subtropical regions worldwide, putting 
approximately 40% of the global population at risk [272].  In these endemic 
regions, pregnant women and children are at the greatest risk and emergence of 
antimalarial drug resistance has intensified efforts in search of new 
chemotherapeutic agents [38, 59].  Currently the most effective drug for dealing 
with malaria infections is artemisinin.  In an effort to decrease further 
development of multi-drug resistance, ACTs are the recommended first line 
therapy endorsed by the WHO [36, 40, 273].  This strategy has been highly 
successful in treating cases of uncomplicated malaria for several years, however 
recent emergence of artemisinin resistance has become a concern [36].  Use of 
artemisinin derivatives as monotherapies or sub-therapeutic dosages has 
contributed to the increase of insensitive Plasmodium strains [36].  With this 
spread of antimalarial resistance, identification of new antimalarials is a priority.  
Widespread use of computational HTS has allowed large sets of compounds to 
be investigated for biological activity [269].  Using this method, suitable lead 
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candidates can be identified from large data sets improving productivity and 
lowering cost to a level more favorable than in vitro screening methods, 
enhancing structure-based drug design [274, 275].  
Previously we identified that PF13_0027 is homologous with the PTP 
superfamily, and investigated the structural characteristics further to determine 
that it is most closely related to MKPs.  Closer investigation of the signature motif 
revealed a native substitution (R398I), which is conserved throughout 
Plasmodium spp.  This single substitution in the conserved MKP homology 
domain is non-consensus defining PF13_0027 is an atypical MAPK 
phosphatase.  We hypothesize that PF13_0027 helps regulate the MAPK 
pathway and may therefore be a candidate for drug design.      
The MKPs in other eukaryotes are critical for intracellular signaling in 
response to numerous types of stimuli [193, 224, 276].  In Plasmodium, 
processes utilizing these proteins may be vital as an intracellular response to 
various external stimuli to regulate stage specific gene expression.  Due to the 
ubiquitous nature of this pathway in eukaryotes, MAPK signaling has been 
studied extensively in model organisms such as yeast [145].  In a broader 
context, increased understanding of this pathway has also contributed 
significantly to cancer research [263, 277, 278].   
In malaria research, MAPK pathways were determined to be critical 
components of sexual proliferation and for the sexual stages [143, 151, 211, 217-
223].  As a potential component of the MAPK signaling pathway, the PF13_0027 
MKP provides an avenue for future drug discovery and warrants further research.  
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Conservation of PF13_0027 orthologs in Plasmodium suggests functional 
significance in parasite blood-stage development as well.  Using the DUSP 
domain of PF13_0027, a homology model was generated and used to screen 
ChEMBL-NTD.  This study utilized the distinct structural features of PF13_0027 
to select an effective drug against this P. falciparum target. 
Materials and Methods 
Identification of Conserved Domains and Evolutionary Lineage   
The sequence of PF13_0027 was retrieved from a public database [279].  
The physicochemical parameters of the amino acid sequence were determined 
using ProtParam [280].  The conserved domains were identified using the 
Conserved Domains Database (CDD) [281], Conserved Domain Architecture 
Retrieval Tool (CDART) [282], InterProScan [283, 284], Prosite [285, 286], 
Superfamily [287], and the Simple Modular Architecture Research Tool (SMART) 
[288, 289].  Ortholog searches were done using NCBI protein BLAST (BLASTP) 
with the full deduced amino acid sequence and individual domains.  Multiple 
sequence alignments were constructed from the retrieved sequences with the 
lowest E-values to identify conserved regions.  The phylogenetic tree was 
inferred using the Neighbor-joining method computing the evolutionary distance 
using the Poisson correlation method with the Molecular Evolutionary Genetics 
Analysis software (MEGA5) [247, 290, 291].   
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Evaluation of Secondary Structure and Post-translational Modifications 
The secondary structure of PF13_0027 was evaluated using JPRED [292] 
and PSIPRED [293, 294].  Phosphorylation sites were assessed using NetPhos 
2.0 [295] which identifies serine, threonine and tyrosine phosphorylation sites, 
and NetPhosK 1.0 [296] to identify kinase binding sites.  Prediction of a signal 
peptide and cleavage site was searched using Signal IP 3.0 [297].  Mitochondrial 
and plastid targeting sequences were searched using the prediction servers 
Predotar [272] and PATS [298-300].  N-terminal myristoylation was investigated 
using the Myristoylator from ExPASy [301]. 
Molecular Modeling and Structure Validation 
The three-dimensional structure of PF13_0027 has not been resolved so a 
homology model was built using the automated protein structure homology 
modeling server Swiss-Model.  Suitable templates for modeling were identified 
using PSI-BLAST in the Swiss-Model repository [205, 302-304].  The crystal 
structure of MKP3 (NCBI Accession No. 1MKP_A) was the most suitable of the 
available templates with greatest sequence coverage and similarity [305].  The 
remaining residues of PF13_0027 not showing any significant similarity were not 
included for homology modeling.  The model was assessed using the atomic 
empirical mean force potential with Atomic Non-Local Environment Assessment 
(ANOLEA), empirical force field with Gröningen Molecular Simulation program 
(GROMOS), and QMEAN6 [303, 306].  The stereochemistry was assessed with 
a minimum resolution of 2.5 Å using PROCHECK [307].  The final structure was 
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also compared to the predicted secondary structure represented using DSSP 
and PROMOTIF [308].  ERRAT plots were generated to check structure quality 
of the template and homology structure using a nine residue sliding window 
[309].  This process was repeated in an iterative fashion until all the residues in 
the plot were not below 95% as done previously [310].  The quality of the final 
structure was also verified using Verify 3D, Procheck and Ramachandran plots 
[307, 311, 312].   
Identification of the Binding Pocket 
The binding pocket was identified using Pocket Finder and Q-site finder 
which uses the Ligsite algorithm [76, 313, 314].  The output of the predicted 
binding pocket was also compared to the Computed Atlas of Surface Topography 
of proteins (CASTp), which uses the alpha shape theory pocket algorithm [315-
317].  The identified pocket was also validated through comparison to the 
structural alignment of the resolved homology model and template (MKP3).   
 Selection of the Compound Dataset and High-throughput in silico Docking   
All docking and scoring calculations were performed using the 2012 
Schrödinger Suite.  The compound library was retrieved from ChEMBL-NTD 
(ftp://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLNTD/) and prepared using 
LigPrep (LigPrep v2.5, Schrödinger LLC).  The homology model, made from 
sequence PF13_0027, was minimized using the OPLS2005 [318] force-field 
algorithm and the grid files were generated in GLIDE (Glide v5.8, Schrödinger 
LLC) [319-321].  The modeled structure was used to identify small molecular 
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inhibitors with affinity to the predicted active site through in silico docking 
experiments using extra precision (XP) mode [321] on a Dell Precision 490 
workstation with an Intel Xeon dual quad-core processors running Ubuntu 
10.04.  From the results obtained, the molecule structures with the highest 
predicted affinity; lowest docking scores within GLIDE's error of 2 kcal/mol to the 
active site were selected.  From this subset, the commercially available 
compounds were identified and used for in vitro culture assays. 
In vitro parasite culture conditions   
P. falciparum NF54 and C9 were cultured according to standard methods 
at 37°C (5% O2 and 5% CO2, nitrogen balanced) in 5% hematocrit (O+ blood) 
and RPMI 1640 medium with 0.5% Albumax II, 0.25% sodium bicarbonate and 
0.01 mg/ml gentamicin [241]. 
In vitro Drug Susceptibility Assay Using SYBR Green I 
Synchronized cultures were seeded into 96-well plates at 0.5% 
parasitemia and cultured for 96 hours under the previously stated conditions.  
Plates were then frozen overnight at -80C.  Plates were thawed for 15 minutes 
then mixed by pipetting.  Eighty microliters of each well were transferred to a new 
96-well plate followed by 100 µL of SYBR Green I (Sigma Aldrich) in lysis buffer 
(0.2 µL of SYBR Green I/mL 2X lysis buffer).  Plates were covered and incubated 
in the dark for 1 hour at room temperature.  Fluorescence intensity was 
measured with a SpectraMax M2e microplate fluorescence reader (Molecular 
Devices) with excitation and emission wavelengths of 485 nm and 525 nm 
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respectively.  The sample values were expressed in relative fluorescence units 
(RFU).  EC50 values were obtained by normalizing the values using control wells 
of samples cultured without drug and plotted using a one-phase exponential dose 
response curve using GraphPad Prism 6 (GraphPad Software Inc.).  
Growth Assay and Cell Cycle Determination 
Parasite cultures were maintained in 96-well plates for 96 hours.  Parasite 
cultures were plated in triplicate with sample collection at six hour intervals.  
Relative fold change of parasite growth in treated cultures was estimated by 
using ethidium bromide intensity as an index for parasite growth and quantified 
using flow cytometry (Appendix C).  Parasite cultures were fixed in 0.05% 
glutaraldehyde after removal of culture medium and permeabilized with 0.3% 
Triton-X 100.  Cultures were then treated with 0.5 mg/mL RNAse A then stained 
with 0.1mg/mL ethidium bromide.  Each sample was then quantified using a C6 
Flow Cytometer H System™ (BD Accuri™).  The data was analyzed using CFlow 
Plus software (BD Accuri™) and GraphPad Prism 6 (GraphPad Software Inc.) 
(Summary of statistical analysis in Appendix G). 
Results 
Evaluation of the Physical Properties of PF13_0027 
Initial evaluation of PF13_0027 included an investigation of potential 
binding sites, phosphorylation sites, and post translational modifications.  These 
methods provided additional insight into potential interactions and function of this 
putative phosphatase through the use of publicly available bioinformatics tools.  
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Through the use of these tools, it was found that there were not any significant 
phosphorylation sites or post translational modifications.  PF13_0027 also did not 
show presence of a signal peptide.  The predicted secondary structure was used 
to validate the homology model and supported the final structure.   
Molecular Structure of PF13_0027  
A crystallographic structure of PF13_0027 has not yet been resolved by 
experimental methods and, neither is there a homologous protozoa protein that 
could be used for a template.  The closest template available in the Swiss Model 
repository was the human phosphatase MKP3 with 21% similarity (Table 3.1 and 
Figure 3.1).  Analysis and validation of the structure using the WHAT-IF web 
interface (version 8) revealed that the structure was in agreement with standard 
structural conditions.  Analysis of the Ramachandran plot gave a Z-score of -
2.972 that was within the expected ranges for well-refined structures with 89.2% 
of the amino acid residues in favored regions (Figure 3.2).  All bonds were in 
agreement with standard bond lengths with a RMS Z-score of 0.669 and RMS 
deviation of 0.015.  The overall quality of the model predicted by ERRAT was 
69.375 compared to 88.235 of the template which was favorable considering the 
numerous INDELs in primary sequence (Figure 3.3).  Additionally, the RMSD 
score from DaliLite of Cα trace between 141 aligned residues of 1MKP and the 
homology model of PF13_0027 DUSP was 0.5 Å with a Z-score of 26.7 and 21% 
sequence identity (Figure 3.4).  The combined results from these various 
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analyses suggest that the homology model of PF13_0027 DUSP is reasonable 
and reliable.  
Active Site Prediction 
The predicted binding pockets for PF13_0027 were identified and 
validated using Qsite-Finder, Pocket Finder and CASTp.  A total of 10 binding 
pockets were found and compared to the active site of the template protein 
(Figure 3.5).  The analysis revealed that the identified pocket in the region of the 
signature motif was highly conserved with the template active site as predicted 
through multiple sequence alignments.  Sequence identity of the catalytic site 
was greater (78%) between the template and homology model than in any other 
region.  This comparison also suggests functional conservation between the 
template and model.  The residues within the binding pocket include the 
signature motif residues of previously characterized active phosphatases.  For 
example, the residues C383, D345 and I398 of PF13_0027 align with the 
conserved C293, D262 and R299 of MKP3.   Conservation of the predicted site 
in the homology model and the validated site in the template suggests that the 
selected pocket was the most favorable for HTS (Figure 3.6).   
Ligand Selection and Drug Susceptibility Assay    
From the ChEMBL-NTD dataset, 10001 compounds were docked and 
ranked according to glide score.  These molecular inhibitors were previously 
screened with P. falciparum 3D7 and have a minimum inhibitory potential of 80% 
validated using LDH activity assays as an index of growth (GSK TCAMS 
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Dataset) or erythrocyte-based proliferation assays (Novartis-GNF Malaria Box 
Dataset) [269, 322].  The bioactive drug-like small molecules in the database all 
adhere to the Lipinski rule-of-five and provide abstracted bioactivities [323].  
Cytotoxicity against human hepatocytoma HepG2 cells was observed in 1982 of 
the compounds tested at 10 µM [269].  These compounds were evaluated on the 
basis of their quality of interaction represented by the GLIDE calculation.  
Commercially available compounds were identified from the results and 7 
compounds (Table 3.2) were obtained (390097; 7,8-Dihydroxy-2H-chromen-2-
one: 524725; 1-(4-Chlorophenyl)-5-oxo-3-pyrrolidinecarboxylic acid: 533073; 2-
((N-[(4-Fluorophenyl)(2-thienyl)methyl]glycyl)amino)-3-thiophenecarboxamide: 
533730; 2-([N-(Diphenylmethyl)glycyl]amino)-3-thiophenecarboxamide: 525841; 
3-[(E)-(1H-Benzimidazol-2-ylhydrazono)methyl]-2-chloro-7-methoxyquinoline: 
579624; 2-[(2E)-2-(1,3-Benzodioxol-5-ylmethylene)hydrazino]-1H-benzimidazole: 
585222; 2-[(2E)-2-(3,4-Dimethoxybenzylidene)hydrazino]-1H-benzimidazole).  
Poses of each compound were resolved to show the interaction of each molecule 
with the active site residues (Figures 3.7-13).    
Growth assays were performed with NF54 parasites while under drug 
pressure with the selected compounds in order to evaluate and contrast the drug 
attenuated phenotype to the insertional mutant phenotype observed with C9 
(Figure 3.14-20).  Since each of the selected compounds had published activity 
against P. falciparum, it was expected that the parasites would be attenuated 
over the course of the assay [269, 322].  The attenuated phenotype of C9, as 
stated previously, presents a prolonged pre-S phase contributing to late entry 
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into S/M development and a fold decrease in parasitemia 50% of the wild type.  
As a starting point, the EC50 drug concentration of each of the selected inhibitory 
compounds was used to challenge the parasites over the course of the 
experiment.  To assess the cell cycle phenotype, the relative abundance of each 
developmental stage was quantified at each time point and plotted using a six-
order polynomial standard curve in order to visualize the function of the 
developmental cycle.  Overlaying the developmental stage growth curves for 
each parasite culture enabled us to determine the course and timing of the cell 
cycle.  The initial published dose response assessment of each compound was 
determined over the course of a 72 hour assay [269].  However, to develop a 
clearer picture of the effect on the cell cycle, it was necessary to observe the 
course of parasite development over two consecutive cycles.  Therefore, 
parasites in this study were cultured and monitored under drug pressure for 96 
hours.  Due to the extended length of the assay, it was possible to observe 
attenuation greater than 50% in most treated cultures.  Each compound 
successfully attenuated pre-S development greater than 30 hours as in the C9 
mutant extending the overall cycle time beyond that of the wild-type (Table 3.3).  
Using Kruskal-Wallis multiple comparison with the Dunn’s post-test, we 
determined that pre-S attenuation was similar to that of the C9 mutant (=0.05).  
In addition to the pre-S phase, the overall timing of the development cycle was 
compared and tested using the same statistical test (=0.05) (Table 3.4).  Both 
cycle time and pre-S phase timing are summarized in figure 3.20.  Each drug 
treated culture also showed a strong similarity to C9 in cycle timing. 
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To evaluate the effects of each of the inhibitors on cultures without the 
proposed target, we set up dose-response assays with both NF54 and C9 to 
compare the efficacy of the compounds in both parasite lines.  In vitro drug 
susceptibility assays also revealed that C9 had reduced susceptibility to 533073, 
533730 and 579624 when compared with NF54 (Table 3.5). 
Discussion 
As an important regulatory process, phosphorylation cascades exert a 
critical influence on cellular development through signal transduction, and as a 
result, have been investigated extensively to elucidate methods of 
chemotherapeutic intervention [224, 324-328].  These pathways have not yet 
been fully characterized in Plasmodium, and as a result, there have not been any 
classes of drugs developed to target phosphorylation-dependent signal 
transduction cascades.  Through preliminary characterizations of PF13_0027 in 
the first part of this study, it was suggested that the pathway utilizing this putative 
phosphatase may fulfill an important role in parasite development.  Building on 
these findings with homology modeling and in silico high-throughput screening, 
our results support the idea that PF13_0027 might be suitable drug target.  In the 
past, computational methods have been successful in identifying potential 
inhibitory compounds using critical components of the developmental cycle [329].  
PF13_0027 presented as a critical component suitable for investigation through 
computational methods.  In P. falciparum, PF13_0027 is the only putative 
phosphatase of its kind, and it is well conserved with single copy orthologs 
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present in P. berghei (PBANKA_140400), P. c. chabaudi (PCHAS_140590), P. 
knowlesi (PKH_140400), P. vivax (PVX_12110), P. cynomolgi (PCYB_141500), 
and P. y. yoelii (PYYM_1407600).  Additionally, PF13_0027 has low homology 
with the closest mammalian orthologs.  These characteristics are often indicators 
of favorable drug targets since unique and conserved genes are typically under 
negative selection making their products essential, and low homology to 
mammalian genes limits adverse effects when targeted with drugs [10, 329].   
Conservation among the Plasmodium parasites, especially P. falciparum 
and P. vivax provides the ability to target both of these parasites, which would be 
a great benefit to antimalarial drug discovery [31, 64].  The conserved binding 
pocket of the homology modeled DUSP domain maintained the necessary 
features for activity and demonstrated an ability to accommodate an inhibitor in 
high-throughput in silico screening.  Considering the structural characteristics, it 
is likely that PF13_0027 interacts with the MAPK signaling pathway which is 
critical and indispensable to eukaryote development, and it would be a major 
contribution to the antimalarial research effort [143, 145, 157, 167, 201, 219, 330, 
331].   
The ChEMBL-NTD contains thousands of compounds with validated 
antimalarial activity [269, 332, 333].  In light of their inhibitory actions, the targets 
and mechanisms of action for most of them in P. falciparum are yet to be 
determined.  Hypothetical malarial modes of action were developed for a few 
compounds to help facilitate their application against Plasmodium through 
historical GSK data regarding biochemical activity with human and microbial 
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targets [269].  In those previous studies, possible targets were inferred.  
Unfortunately, none of the hypothetical targets were associated with the 
compounds identified through the in silico screen in this current study.  This 
computational study, however, enabled us to sort through the database to isolate 
the likely inhibitory compounds and allow us to correlate the proposed binding 
interaction to a phenotype of an attenuated parasite line.     
In order to determine if our protein of interest was being targeted by the 
identified inhibitory compounds, it was necessary to follow up the preliminary 
characterization of PF13_0027 with in silico methods of analysis using the 
homology modeled DUSP.  Replicating the phenotype observed in C9 with 
selected inhibitors would suggest a potential mechanism of action.  Additionally, 
comparing the susceptibility of NF54 and C9 would give further insight into the 
potential targeting of PF13_0027.  This method would help facilitate lead 
identification and optimization progressing toward structure-based drug 
discovery.  Though further studies would be required to determine the precise 
inhibitory mechanism, this study demonstrates a novel translational method 
bridging the gap between insertional mutagenesis and drug discovery.   In vitro 
attenuated growth analysis led to replication of the attenuated mutant phenotype 
with the identified compounds and revealed that 524725, 533073 and 533730 
have lowered efficacy against C9 parasites compared to the wild-type, validating 
this approach and enabling us to postulate a therapeutic target of this inhibitor.  
In addition to replicating the phenotype, observation of increased NF54 
susceptibility compared to C9 makes it possible to suggest PF13_0027 may be 
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involved in the drug response phenotype in the assay.  One of the main 
challenges to post genomic biology is translating a pathogen’s genome to new 
drugs and combinatorial methods with HTS allow us to identify suitable lead 
candidates from a chemical database contributing to drug development efforts 
and accelerating structure based design.  In practice, experimentally determined 
structures are preferred for in silico studies; however the number of 
pharmaceutical targets of interest has far outpaced the ability to experimentally 
develop protein structures [274].  As a result, homology modeling has become 
the popular method of investigation for the growing number of interesting 
pharmaceutical targets.  Comparisons of docking results from both homology 
models and experimentally validated structures have also produced comparable 
results [181, 334].    Utilization of multiple strategies is necessary in order to 
advance the base of knowledge in this field.  In this dissertation research study, 
we proposed a method to translate the information obtained from random 
insertional mutagenesis into a drug discovery strategy using in silico methods.  
The technique employs both experimental and computational methods to identify 
drug compounds, which would be vital to the search for new antimalarials.        
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Table 3.1: Templates identified for homology modeling. 
 
Chain Z rmsd lali nres %id Description 
1mkp-A 26.7 0.5 141 144 21 MKP3/ PYST1 
3lj8-A 20.5 1.8 140 146 24 Tyrosine-protein Phosphatase 
2hxp-A 18.1 2.1 136 144 21 DUSP 9 
1zzw-B 17.9 2.1 134 147 21 DUSP10 
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Figure 3.1: Alignment of potential homology modeling templates.  Potential 
templates were identified in Swiss Model and aligned in JalView.  The 
regions of greatest identity are marked with green.  Below, the alignment of 
the sequences shows the conserved regions in both the primary and 
secondary structure. 
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Figure 3.2: The quality of the model was validated by Ramachandran plot.  
The homology model was found to have 89.2% of the residues in favorable 
positions. 
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Figure 3.3: Overall quality assessment of the model evaluated using 
ERRAT. The comparison of the template crystal structure and homology 
model. (A) PF13_0027 (B) MKP3   
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Figure 3.4: Homology model of PF13_0027.  The structure of PF13_0027 
(brown) was developed using the crystal structure of MKP3 as a template 
(PDB 1MKP).  Alignment of the model with MKP3 (green) revealed that the 
final structure showed the catalytic residues aligned to the proposed 
positions in the active site.  The presence of the signature motif insertion 
does not affect the shape of the active site and forms an alpha-helix 
adjacent to the binding pocket without obstructing the site. 
 
D345
C383
I398
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Table 3.2: Selected ChEMBL-NTD compounds used for in vitro screening. 
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Figure 3.5: Identified binding site of PF13_0027 in the DUSP domain.  The 
binding pocket (red mesh) aligned with the predicted active site identified 
by homology alignments with the template and other phosphatases.  The 
presence of the signature motif insertion does not obstruct the binding site.  
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Figure 3.6: Vacuum electrostatics of the PF13_0027 DUSP homology 
model.  The blue signifies slight positive charge while the red shows the 
negatively charged regions of the domain.  The slight positive charge of the 
binding pocket (circled) shows that it would be favorable for binding of a 
negatively charged phosphate group.  The predicted surface charges of the 
homology model help validate the quality of the structure for docking.  
 
 93 
 
 
  
 
 
Figure 3.7: Orientation of 390097 in the binding pocket with LIGPLOT. 
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Figure 3.8: Orientation of 524725 in the binding pocket with LIGPLOT. 
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Figure 3.9: Orientation of 533073 in the binding pocket with LIGPLOT. 
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Figure 3.10: Orientation of 533730 in the binding pocket with LIGPLOT. 
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Figure 3.11: Orientation of 525841 in the binding pocket with LIGPLOT. 
 
525841
N389
C383
D345
I398
525841
 98 
 
  
 
 
Figure 3.12: Orientation of 579624 in the binding pocket with LIGPLOT. 
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Figure 3.13: Orientation of 585222 in the binding pocket with LIGPLOT. 
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Figure 3.14: NF54 parasites challenged with compound 390097.  The plots 
represent the asexual growth cycle of parasites treated with compound 
390097 and the comparison to untreated NF54 and C9.  The cycle was 
determined by overlaying the relative abundance of rings (blue), 
trophozoites (red) and schizonts (green). 
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Figure 3.15: NF54 parasites were challenged with compound 524725.  The 
plots represent the asexual growth cycle of parasites treated with 
compound 524725 and the comparison to untreated NF54 and C9.  The 
cycle was determined by overlaying the relative abundance of rings (blue), 
trophozoites (red) and schizonts (green). 
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Figure 3.16: NF54 parasites were challenged with compound 533073.  The 
plots represent the asexual growth cycle of parasites treated with 
compound 533073 and the comparison to untreated NF54 and C9.  The 
cycle was determined by overlaying the relative abundance of rings (blue), 
trophozoites (red) and schizonts (green). 
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Figure 3.17: NF54 parasites were challenged with compound 533730.  The 
plots represent the asexual growth cycle of parasites treated with 
compound 533730 and the comparison to untreated NF54 and C9.  The 
cycle was determined by overlaying the relative abundance of rings (blue), 
trophozoites (red) and schizonts (green). 
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Figure 3.18: NF54 parasites were challenged with compound 525841.  The 
plots represent the asexual growth cycle of parasites treated with 
compound 525841 and the comparison to untreated NF54 and C9.  The 
cycle was determined by overlaying the relative abundance of rings (blue), 
trophozoites (red) and schizonts (green). 
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Figure 3.19: NF54 parasites were challenged with compound 579624.  The 
plots represent the asexual growth cycle of parasites treated with 
compound 579624 and the comparison to untreated NF54 and C9.  The 
cycle was determined by overlaying the relative abundance of rings (blue), 
trophozoites (red) and schizonts (green). 
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Figure 3.20: NF54 parasites were challenged with compound 585222.  The 
plots represent the asexual growth cycle of parasites treated with 
compound 585222 and the comparison to untreated NF54 and C9.  The 
cycle was determined by overlaying the relative abundance of rings (blue), 
trophozoites (red) and schizonts (green). 
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Table 3.3: Comparison of average pre-S phase times in treated cultures to 
NF54 and C9.  P-values represent comparison of each sample to C9. 
 
Sample Pre-S (hrs) p-value 
390097 34.332.08 0.676 
524725 34.674.16 0.734 
533073 35.335.77 0.676 
533730 30.671.15 0.071 
525841 34.676.49 0.480 
579624 35.001.73 0.979 
585222 34.002.00 0.638 
NF54 26.671.15 0.008 
C9 36.004.00 - 
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Table 3.4: Comparison of average cycle times in treated cultures to NF54 
and C9.  P-values represent comparison of each sample to C9. 
 
Sample Cycle (hrs) p-value 
390097 58.672.30 0.338 
524725 49.331.15 0.147 
533073 55.001.00 0.959 
533730 53.333.05 0.698 
525841 58.003.46 0.484 
579624 47.335.03 0.097 
585222 59.337.02 0.484 
NF54 47.331.15 0.052 
C9 56.331.52 - 
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Figure 3.21: Comparison of cycle times and pre-S phase for treated and 
untreated cultures.  The blue bars represent the pre-S phase of 
development.  Attenuated development is represented by a longer pre-S 
phase compared to NF54.  Each treated culture and C9 show an extended 
pre-S phase.  The total cycle time is represented by the red bars in each 
sample. 
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Table 3.5: Comparison of NF54 and C9 susceptibility to the selected 
compounds.  Compounds 5333073, 533730 and 579624 also show NF54 to 
have significantly greater susceptibility. 
 
Compound ID EC50 NF54 (nM) EC50 C9 (nM) P-value 
390097 340.253.6 248.933.7 0.1124 
524725 503.136.5 248.462 0.0240 
533073 471.937.4 1227.386.3 0.0013 
533730 196.3113.8 510.951.6 0.0073 
525841 186.133.8 224.748.1 0.5467 
579624 13633.1 58439.86 0.0010 
585222 378.897.7 339.328 0.7070 
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Chapter 4: Conclusions and Future Directions 
The studies described in this dissertation provide novel insights into a 
putative phosphatase of P. falciparum.  The presented data not only provides an 
understanding of basic parasite biology, but provides a foundation for new 
methods to reduce malaria transmission.  Similar to the strategies utilized to 
target signaling pathways in cancer research, the manipulation of signaling 
pathways in Plasmodium can potentially support the development of 
antimalarials capable of attenuating parasite development.  The major findings of 
this dissertation are that PF13_0027 is critical for development of the P. 
falciparum trophozoite, and can be targeted for drug discovery.  My results also 
demonstrate that molecular modeling and in silico HTS can be used to translate 
discoveries of critical genes identified through transposon-mediated random 
insertional mutagenesis with pB into discoveries of new classes of antimalarial 
drugs.    
The first part of this dissertation focuses on an attenuated parasite line 
(C9) that has an insertional knockout of PF13_0027 and investigates the 
phenotype to determine the functional role.  My data demonstrates that this gene 
is important for pre-S development of the asexual trophozoite and that insertional 
knockout attenuates blood stage cycling by delaying entry into the S/M schizont.  
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Through complementation using the ORF with the 700 bp 5’ UTR promoter 
region, the WT phenotype can be rescued, validating the critical nature of 
PF13_0027 to development.  Structural assessment of the domain architecture 
and conserved regions reveals that not only does PF13_0027 have MKP 
homology, but that it is missing a conserved residue in the signature motif, a 
characteristic that is also common in STYX domains.  The unique characteristics 
in this putative phosphatase support that it could be a pseudophosphatase that 
modulates the activity of the MAPK pathway through a dominant-negative 
approach, or a low activity phosphatase.     
The second part of this dissertation investigates the potential of targeting 
PF13_0027 for drug discovery through in silico HTS using a homology model of 
the DUSP domain.  Using this procedure we attempted to chemically reproduce 
the attenuated phenotype observed in C9 using molecular inhibitors from 
ChEMBL-NTD.  This procedure utilized the combined data sets of GSK-TCAMS, 
Novartis-GNF malaria box and St. Jude Children’s Research hospital datasets.  
Assessment of the attenuated phenotype of parasites treated with each of the 
inhibitors reveals that the cell cycle of NF54 parasites is attenuated similar to that 
of C9 when treated with the selected compounds suggesting that an inhibitor 
identified through in silico methods could be used to replicate the attenuated 
phenotype in vitro.  This conclusion is important since this experiment, as a 
proof-of-concept, shows that in silico methods may be used to rapidly sort and 
translate the large library of data developed through large-scale insertion 
mutagenesis into advanced insights in drug discovery.  It also allows us to sort 
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through large databases of small molecules to find valuable structures for future 
structure-based drug design.   
Taken together, the data presented in this dissertation show that 
PF13_0027 is a very important component in asexual development and 
proliferation.  It also provides new insight into the importance of MAPK signaling 
cascades to Plasmodium development.  Future studies will focus on identification 
of downstream signaling pathways and potential substrates.  Additionally in depth 
proteomic studies involving structural characterization, recombinant expression, 
and functional in vitro assays will be able to generate a more specific 
understanding of interacting substrates and the effects of potential inhibitors.  
Current advancements in molecular and computational biology techniques 
enable accurate representations of molecular interactions between potential drug 
targets and molecular inhibitors.  This study demonstrates that these methods 
will augment current efforts expanding our knowledge of parasite biology and 
help identify new drugs.     
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Appendix A: Transfection Plasmids 
 
 
Figure AI: The helper plasmid codes for the piggyBac transposase used in 
random insertional mutagenesis.  This helper plasmid was used in both the 
initial transfection that knocked out PF13_0027 and in the complementation 
experiments. 
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Appendix A: continued 
 
 
Figure AII: Plasmid used for the initial transfection knocking out PF13_0027.  
The region between the ITRs was randomly inserted into the N-terminal 
region of PF13_0027.   
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Appendix A: continued 
 
 
Figure AIII: Plasmid used for complementation of C9.  Complementation of 
C9 with PF13_0027 required this construct with the N-terminal intergenic 
promoter region (above schematic) and 3’CAM termination sequence.  To 
differentiate transfected clones a BSD selection marker was used in this 
second round of transfection.   
 
pL-BACII-HBH 
PF13_0027
PF13_0027
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Appendix B: Primers  
Table BI: Primer list 
Gene Primers 
PCR 
PF13_0027 
5′-CACCCTACCCCTGTATTATTTCCTACCCTC-3  
5′-GTTTATGTAATTATTTATTACTATAAATGGTC-3  
BSD 
5′-GCCCTCCCACACATAACCAGAGGGCA-3′ 
5′-GCCTTTGTCTCAAGAAGAATCCACCCT-3′ 
hDHFR 
5′-ATGGTTGGTTCGCTAAACTG-3′ 
5′-TTAATCATTCTTCTCATATACTTCAAA-3′ 
Episome 
5′-AGATGTCCTAAATGCACAGCGAC-3′ 
5′-CAGGAAACAGCTATGAC-3′ 
 
RT-PCR 
PF13_0027 
5′-CACCATGGAATATAAAAGCATCGATTTTG-3′ 
5′-GTTTATGTAATTATTTATTACTATAAATGGTC-3′ 
18S RNA 
5′-AACCTGGTTGATCTTGCCA-3′ 
5′-GTATTGTTATTTCTTGTCACTACCTCTC-3′ 
 
qRT-PCR 
PF13_0027 
5′-TCGATTTTGAGGAGCTGAA-3′ 
5′-GGGTAAAACATCCTTTTTGTT-3′ 
  
Southern Blot 
Probe 
5′-ATAAGAAGAAGTATATAATGAATTATATATAATGCT-3′  
5′-CATATGTATTTTTTTTGTAATTTCTGTGTTTAT-3′ 
  
Site-directed Mutagenesis 
D345A 
5′-CTTTATGTACAAACCAAGTAAAAGCTAATAATACATCATTTATAAAAC-3′ 
5′-GTTTTATAAATGATGTATTATTAGCTTTTACTTGGTTTGTACATAAAG-3′ 
C383A 
5′-CAAAATAATATCCTTATTATAGCTAATCATGGAATGAAAAATCCTAC-3′ 
5′-GTAGGATTTTTCATTCCATGATTAGCTATAATAAGGATATTATTTTG-3′ 
K388A/ 
K394A 
5′-GTAATCATGGAATGGCAAATCCTACATCAGAAGCAACAAATAGTATAAGTC-3′ 
5′-GACTTATACTATTTGTTGCTTCTGATGTAGGATTTGCCATTCCATGATTAC-3′ 
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Appendix C: Flow Cytometry Gating 
 
 
Figure CI: Gating used to sort the different developmental stages of asexual 
P. falciparum cultures by flow cytometry.  Ring stages with a lower DNA 
content fluoresce at a lower wavelength in both the FL1-A and FL3-A 
channels when stained with ethidium bromide, compared to the later stages.  
Throughout development, as the parasites mature the wavelength of light 
fluorescing off the infected cells in both channels increases.  By using tightly 
synchronized cultures, we are able to determine the precise pattern and 
format the gate accordingly to sort different developmental stages.  The 
relative abundance of each developmental stage is then measured and 
plotted.  Overlaying these plots give us a graph that compared the relative 
abundances and allows us to determine the cell cycle timing and 
progression. 
 
Schizonts
Trophozoites
Rings
Uninfected cells
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Appendix D: Whole genome sequencing.   
Table DI: Transposon insertions and SNPs in the genomes of NF54, C9 and 
the complemented parasite lines.  A single SNP in the putative clathrin coat 
assembly protein AP180 was present in all samples.  This experiment also 
validated that the complementation of C9 was episomal 
 
Clone Chromosome Position pB Gene Epi SNP SNP gene 
NF54 - - N N N 1 PFIT_1246000 
C9 13 271811 Y PF13_0027 N 1 PFIT_1246000 
E3 13 271811 Y PF13_0027 Y 1 PFIT_1246000 
E8 13 271811 Y PF13_0027 Y 1 PFIT_1246000 
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Appendix E: Southern Blot of complemented parasites 
 
Figure EI: Southern blot analysis of the transfected clones.  Using a probe 
specific to the BSD selection cassette produced signals representative of the 
complementation plasmid (arrows).   
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Appendix F: PCR Validation of complemented clones 
 
 
Figure FI: PCRs used to validate the complemented parasite clones.  The 
hDHFR sequence (567 bp) is only present in the parasites that carried the 
original transposon used to knock out PF13_0027 and was present in all 
sequences except NF54.  The BSD sequence (393 bp) was present in only 
the positive transfectants and was not present in C9 or NF54.  The third 
reaction was used to test for the presence of the intact complementation 
plasmid as an indication of episomal retention (608 bp) and was present in 
all the clones.  The fourth reaction used the Southern blot probe (711 bp) as 
an additional validation that the selected clones carried the complementation 
plasmid. 
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Appendix G: Statistical Analysis Tables 
Table GI: Growth assay analysis for NF54, C9, E3 and E8 
 
 
 
Number of families 1
Number of comparisons 
per family 6
Alpha 0.05
Dunn's multiple 
comparisons test Significant?
NF54 vs. C9 Yes
NF54 vs. E3 No
NF54 vs. E8 No
C9 vs. E3 Yes
C9 vs. E8 Yes
E3 vs. E8 No
Kruskal-Wallis test
P value 0.0038
Do the medians vary signif. (P < 0.05) Yes
Number of groups 4
Kruskal-Wallis statistic 13.44
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Appendix G: continued 
Table GII: Invasion assay analysis for NF54, C9, E3 and E8 
 
 
 
Number of families 1
Number of comparisons 
per family 6
Alpha 0.05
Dunn's multiple 
comparisons test Significant?
C9 vs. E3 Yes
C9 vs. E8 Yes
C9 vs. NF54 Yes
E3 vs. E8 No
E3 vs. NF54 No
E8 vs. NF54 No
Kruskal-Wallis test
P value 0.0152
Do the medians vary signif. (P < 0.05) Yes
Number of groups 4
Kruskal-Wallis statistic 8.128
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Appendix G: continued 
Table GIII: Growth assay analysis for NF54, C9, D345A, C383A, and 
K388A/ K394A 
 
 
 
 
Number of families 1
Number of comparisons per family 10
Alpha 0.05
Dunn's multiple comparisons test Significant?
NF54 vs. C9 Yes
NF54 vs. C383A Yes
NF54 vs. D345A Yes
NF54 vs. K388A K394A No
C9 vs. C383A No
C9 vs. D345A No
C9 vs. K388A K394A Yes
C383A vs. D345A No
C383A vs. K388A K394A Yes
D345A vs. K388A K394A Yes
Kruskal-Wallis test
P value 0.0031
Exact or approximate P value? Exact
Do the medians vary signif. (P < 0.05) Yes
Number of groups 5
Kruskal-Wallis statistic 11.05
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Appendix G: continued 
Table GIV: Invasion assay analysis for NF54, C9, D345A, C383A, and 
K388A/ K394A 
 
 
 
 
Number of families 1
Number of comparisons per family 10
Alpha 0.05
Dunn's multiple comparisons test Significant?
NF54 vs. C9 Yes
NF54 vs. C383A Yes
NF54 vs. D345A Yes
NF54 vs. K388A K394A No
C9 vs. C383A No
C9 vs. D345A No
C9 vs. K388A K394A Yes
C383A vs. D345A No
C383A vs. K388A K394A Yes
D345A vs. K388A K394A Yes
Kruskal-Wallis test
P value 0.0003
Exact or approximate P value? Exact
Do the medians vary signif. (P < 0.05) Yes
Number of groups 5
Kruskal-Wallis statistic 12.23
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Appendix H: Bioinformatics 
Table HI: Bioinformatics Resources 
Tool Version URL 
Databases 
  
PlasmoDB 9.2 http://plasmodb.org/plasmo/ 
GenBank 194 http://www.ncbi.nlm.nih.gov/genbank/ 
ChEMBL-NTD 
 
https://www.ebi.ac.uk/chemblntd 
Prosite 20.89 http://prosite.expasy.org/ 
Superfamily 1.75 http://supfam.cs.bris.ac.uk/SUPERFAMILY/ 
Prediction and Characterization 
ProtParam 
 
http://web.expasy.org/protparam/ 
CDD 
 
http://www.ncbi.nlm.nih.gov/cdd/ 
CDART 
 
http://www.ncbi.nlm.nih.gov/Structure/lexington/lexington.cgi 
InterProScan 4.8 http://www.ebi.ac.uk/Tools/pfa/iprscan/ 
SMART 7 http://smart.embl-heidelberg.de/ 
NCBI BLASTP 
 
http://blast.ncbi.nlm.nih.gov/Blast.cgi 
JPRED 3 http://www.compbio.dundee.ac.uk/www-jpred/ 
PSIPRED 3.2 http://bioinf.cs.ucl.ac.uk/psipred/ 
Net Phos 2.0 2 http://www.cbs.dtu.dk/services/NetPhos/ 
Net PhosK 1.0 1 http://www.cbs.dtu.dk/services/NetPhosK/ 
Predotar 1.03 http://urgi.versailles.inra.fr/predotar/predotar.html 
PATS 1.2.1 http://gecco.org.chemie.uni-frankfurt.de/pats/pats-index.php 
Modeling 
  
Swiss-Model 
 
http://swissmodel.expasy.org/ 
Structure Validation 
  
ANOLEA 
 
http://protein.bio.puc.cl/anolea/index.html 
GROMOS 
 
http://www.gromacs.org/Documentation/Terminology/Force_Fields/GROMOS 
QMEAN6 
 
http://swissmodel.expasy.org/qmean/cgi/index.cgi 
PROCHECK 
 
http://www.ebi.ac.uk/thornton-srv/software/PROCHECK/ 
DSSP 2 http://swift.cmbi.ru.nl/gv/dssp/ 
PROMOTIF 3 http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=n/a&template=doc_promotif.html 
ERRAT 2 http://nihserver.mbi.ucla.edu/ERRATv2/ 
Verify3D 
 
http://nihserver.mbi.ucla.edu/Verify_3D/ 
RAMPAGE 
 
http://mordred.bioc.cam.ac.uk/~rapper/rampage.php 
Pocket Finder 
 
http://www.modelling.leeds.ac.uk/pocketfinder/help.html 
Q-Site Finder 
 
http://www.modelling.leeds.ac.uk/qsitefinder/ 
CASTp 
 
http://sts.bioengr.uic.edu/castp/calculation.php 
WHAT-IF 8 http://swift.cmbi.ru.nl/whatif/ 
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Appendix I: Content Permissions 
Malaria life cycle: 
 Content Providers: CDC/Alexander J. da Silva, Ph.D/ Melanie Moser 
 Permission: PD-USGov-HHS-CDC 
 This image is in the public domain and thus free of any copyright 
restrictions.  As a matter of courtesy we request that the content 
provider be credited and notified in any public or private usage of the 
image.  
 http://www.dpd.cdc.gov/dpdx/images/ParasiteImages/M-
R/Malaria/malaria_LifeCycle.gif 
 
Maps 
 Malaria Atlas Project  
 Creative Commons Attribution 3.0 Unported (CC by 3.0) 
 Free to share (copy, distribute and transmit the work); remix (adapt 
the work); make commercial use of the work. 
http://creativecommons.org/licenses/by/3.0/ 
 http://www.map.ox.ac.uk/ 
 
 
 
 
 
